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Norsk Sammendrag 
Vurdering av venstre ventrikkels størrelse og funksjon er helt sentral ved enhver 
ekkokardiografisk undersøkelse og den vanligste kliniske indikasjon for å utføre ultralyd av 
hjertet. I dette prosjektet ble hjertefunksjonen hovedsakelig undersøkt ved hjelp av 
todimensjonal og tredimensjonal beregning av ejeksjonsfraksjon, hastighetsmålinger i 
hjertemuskelen ved hjelp av vevsdoppler, todimensjonal og tredimensjonal speckle tracking 
(mønsterfølging) og visuell vurdering av veggfortykkelse i gråtonebildet. Et viktig mål med 
prosjektet var å evaluere tradisjonelle og moderne ekkokardiografiske metoders repeterbarhet 
og evne til å detektere endringer i hjertets kontraktilitet. Et annet hovedmål var å validere 
nøyaktigheten av direkte ekkokardiografisk beregning av hjerteinfarktstørrelse, og å evaluere 
nytteverdien av 3D ekkokardiografi hos pasienter med hjerteinfarkt. 
Artikkel 1:  
10 friske forsøkspersoner ble undersøkt med ekkokardiografi av 2 ulike leger, som hver for 
seg analyserte ulike mål på hjertefunksjon både på sine egne opptak (2 ganger) og på den 
andre legens ultralydopptak. Repeterbarheten av målingene ble analysert. Alle mål hadde 
akseptabel repeterbarhet, men målinger som var gjennomsnitt av flere enkeltmålinger hadde 
best repeterbarhet. Repeterbarheten var bedre når det samme ultralydopptaket ble analysert 2 
ganger, sammenlignet med når legene analyserte to ulike ultralydopptak. 
Artikkel 2:  
33 friske forsøkspersoner ble undersøkt med ekkokardiografi i hvile, under medikamentstress 
med lavdose dobutamin og etter injeksjon av beta-blocker. Ulike ekkokardiografiske metoders 
relative endring fra hvile til stress og fra hvile til beta-blokker påvirkning ble undersøkt. 
Studien viste at det var et markert skille mellom hastighetsrelaterte målinger tidlig i hjertets 
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sammentrekningsfase (systolen) og slagvolumrealterte ende-systoliske målinger. 
Hastighetsrelaterte målinger som klaffeplanhastighet, strain rate og blodstrømshastighet i 
utløpstraktus var mest følsomme for endringer i kontraktilitet, noe som kan indikere at disse 
målingene også er best egnet for å påvise endringer i hjertefunksjonen i klinisk praksis.  
Artikkel 3:  
I studien valideres direkte automatisert ekkokardiografisk beregning av hjerteinfarktstørrelse, 
som er en ny metode utviklet ved vårt institutt, på 58 pasienter med gjennomgått førstegangs 
hjerteinfarkt og 35 kjønns- og aldersmatchede friske fra Helseundersøkelsen i Nord 
Trøndelag. Den nye metoden er basert på fargekodet vevsdoppler strain rate med manuell 
korreksjon ut i fra visuell vurdering av veggfortykkelse i gråtonebildet. Metoden skilte best 
mellom små og store infarkter når infarktstørrelse på 12% ble benyttet som cut-off, og hadde 
høyere korrelasjon med kontrast-MR sammenliknet med ejeksjonsfraksjon, speckle tracking 
basert global strain, visuell vurdering av veggfortykkelse, langakseforkortning og 
klaffeplanhastighet. Rapportering av prosentvis infarktstørrelse i stedet for funksjonelle mål 
vil være enklere å forstå for pasienter og helsepersonell uten kjennskap til avansert 
ekkokardiografisk terminologi. 
Artikkel 4:  
I denne studien ble de samme personene som deltok i studie 3 undersøkt med 2D og 3D 
ekkokardiografi. Visuell vurdering av veggfortykkelsen med 3D ekkokardiografi var spesielt 
nyttig ved undersøkelse av pasienter med godt akustisk vindu fra hjertets apex. Totalt sett var 
visuell vurdering av veggfortykkelsen med 2D og 3D ekkokardiografi og 2D speckle tracking 
basert strain mer nøyaktig enn måling av ejeksjonsfraksjonen og 3D speckle tracking basert 
strain ved måling av global og regional funksjon, når kontrast-MR ble benyttet som 
referansemetode. 
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1 Introduction 
1.1 Echocardiography 
Echocardiography is the most widely used method for assessing left and right ventricular 
function, valvular disease and cardiac abnormalities (1).  
1.1.1 Selected history of cardiac ultrasound in Trondheim 
The history of cardiac ultrasound started in Sweden with Edlers description of cardiac 
structures by the ultrasound reflectoscope already in 1953 (2). Subsequent pioneer research 
led to the development of continuous and pulsed wave Doppler and the first presentation of 
real-time two-dimensional (2D) real-time cardiac images by Hertz and Asberg in 1967. 
However, invasive catheterization remained the main method to assess cardiac function for 
still some years. Further development and validation of cardiac ultrasound was necessary, and 
in Trondheim, Liv Hatle and Bjørn Angelsen made important contributions in validating the 
Doppler methods as tools for diagnosing and monitoring cardiac diseases. Angelsen and 
colleagues developed the pulsed echo Doppler flow velocity meter (PEDOF) which was the 
basis for the first publication of non-invasive assessment of pressure gradient in mitral 
stenosis by Holen in 1976 (3). Subsequently, several pioneering studies were conducted by 
Hatle, Angelsen, Brubakk, Skjærpe and colleagues on the clinical use of Doppler showing 
that non-invasive Doppler examination could replace cardiac catheterization in diagnosing 
different non-coronary cardiac diseases (4-8). These developments were followed by new 
important studies for the diagnosis of cardiac disease by the Trondheim group. Estimation of 
the valve area in patients with aortic stenosis and hemodynamic evaluation of aortic 
prostheses by Doppler ultrasound and 2D echocardiography were described (9-11). The 
Trondheim group contributed to better understanding of the diastolic function and showed 
 12 
that left ventricular (LV) diastolic pressures could be estimated by pulmonary venous flow 
Doppler (12). The technical – clinical cooperation continued, with Hans Torp as an important 
contributor on the technical (software) side. The aortic and mitral blood flow profiles were 
described in detail by 2D and three-dimensional (3D) colour flow Doppler (13, 14). 
Contributions to better understanding of the LV function and the ventriculo-arterial 
interaction in patients with hypertension were published (15, 16). The accuracy of contrast 
echocardiography compared with magnetic resonance imaging has been evaluated (17). 
Pioneer research and validation of strain and strain rate by tissue Doppler (TD) in Trondheim 
started a new international era in cardiac research (18-21). Validation of new methodology 
based on tissue Doppler and 3D endocardial surface reconstruction in patients undergoing 
dobutamine stress echocardiography were performed (22, 23), and the feasibility of automated 
analysis of myocardial deformation was demonstrated (24, 25). More recently, strain 
measurements by speckle tracking have been validated against magnetic resonance imaging 
(26), and reference values for strain, strain rate and annular velocities have been established 
(27, 28). The ultrasound research group is currently part of the department of Circulation and 
Medical Imaging, NTNU, and a substantial part of ultrasound research in fields like 3D-
echocardiography, high frame rate in 2D tissue Doppler imaging, handhold ultrasound (29) 
and blood flow imaging (30), is done in collaboration with MI-lab.   
1.1.2 Grey scale and Doppler echocardiography 
Ultrasound is generated by piezoelectric crystals that vibrate when being compressed and 
decompressed. The same crystals can act as receivers of reflected ultrasound from reflecting 
structures, usually termed scatters. The amplitude of the reflected ultrasound pulse and the 
distance from the probe can be displayed on monitors as brightness-points as in M-mode 
(motion-mode) or B-mode (brightness mode) images. Grey scale echocardiography by M-
mode was the first ultrasound modality that displayed moving echoes from the heart and is 
 13 
still an important tool in clinical practice. Cardiac structures are displayed on the vertical axis 
corresponding to the distance from the transducer while the horizontal axis gives the time 
period. The high resolution of M-mode (up to 1000 FPS (frames per second)) is favourable in 
the timing of events in the cardiac cycle. M-mode is also frequently used for estimation of 
chamber sizes and the long axis function.  
Grey scale echocardiography by B-mode is the most important ultrasound mode for 
visual evaluation of cardiac anatomy and function, and is also used as underlying guiding tool 
when cardiac function is quantified. Visualization of the endocardial surface in B-mode 
recordings enables measurements of chamber volumes and ejection fraction. Left ventricular 
ejection fraction (LVEF) is the most widely used measurement of global LV systolic function. 
B-mode recordings also allow judgement of the regional function by visual judgement of wall 
thickening during the cardiac cycle, but the temporal resolution is far lower than M-mode. 
The frame rate depends on the sector width and depth, as well as the line density (lateral 
resolution). Typically, a 2D sector covering the left ventricle has a frame rate of about 50 
FPS.  
The Doppler methods are based on detection of the Doppler shift from moving scatters 
(31). The frequency of reflected ultrasound is altered by moving targets (red blood cells or 
myocardium). The Doppler shift for reflected ultrasound (fd  =  f – f0) and subsequently the 
velocity (v) of the moving target (blood cells or myocardium) are given (Eq. 1 and Eq. 2): 
Eq. 1:    fd  ≈  2 * fo * v * cos(T) / c    
        
Eq. 2:            v  ≈  fd * c / 2 * fo * cos(T)    
where fd = Doppler shift, fo = transmitted frequency, v = target (blood or myocardium) 
velocity, T = insonation angle (between ultrasound beam and velocity vector) and c = velocity 
of sound in tissue (≈1540 m/s). 
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The alignment between the ultrasound beam and velocity direction is a crucial point in 
all Doppler analyses. Misalignment less than ±15 degrees will cause ≤3.5% error in the 
measurement and misalignment more than ±30 degrees will cause ≥13% error.  
Blood flow velocity can be measured within a specific site (sample volume) by pulsed 
wave Doppler or all velocities along the ultrasound beam by continuous wave Doppler. By 
continuous wave Doppler the beam is transmitted continuously, and the received echoes are 
sampled continuously. Thus, there is no information about the depth of the different signal 
components. In pulsed wave Doppler, a new pulse cannot be transmitted before the last signal 
has returned. In clinical practice this means that for pulsed wave Doppler, the ability to 
measure high velocities decreases when the distance to the sampled volume is increased. 
Thus, both methods have limitations: pulsed wave Doppler has velocity ambiguity at high 
velocities, and continuous wave Doppler has depth or range ambiguity. Spectral Doppler has 
an effective frame rate of about 300 FPS. 
Pulsed and continuous waved Doppler is displayed in spectral analyzers according to 
the velocity (amplitude), intensity and timing of the reflected ultrasound frequencies (Figure 
1). Gain settings are important for optimal measurements in the Doppler spectrum both for 
pulsed and continuous wave Doppler. The reflected signal of tissue echoes has high intensity 
but low velocity. Blood has high velocity with a wider distribution, but lower intensity. For 
blood flow Doppler, a high pass filter (low velocity reject) is applied to suppress the tissue 
echoes. A low pass filter (high velocity reject) may be applied to suppress noise above the 
velocity range. In tissue Doppler, the high pass filter can be removed, or at least partially, to 
allow the low velocities from the tissue (usually on the order of 1/10 of flow). The blood 
signal can be removed both by reducing the gain, and by applying a low pass filter (high 
velocity reject). 
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 In colour TD each Doppler signal consists of fewer samples per time unit than in 
pulsed wave spectral TD, and the mean Doppler frequency is estimated by the autocorrelation 
technique, causing lower absolute velocities compared with the spectral TD method. Each 
pixel in the ultrasound image is colour coded according to the velocity, and the B-mode and 
colour TD images are displayed superposed, but with multiple of colour Doppler images 
hidden between each B-mode frame. By off-line post processing, either semi quantitative 
analysis in curved anatomical M-mode or quantitative data may be extracted. When picking 
one region of interest, corresponding velocity, motion, and strain rate data are presented in 
time trace (Figure 1).                                                                                                                                             
           
Figure 1. Spectral land trace analyses of flow and tissue Doppler velocity curves with 
velocity shown on the y-axis and time on the x-axis. Left figure: maximal velocity through a 
stenotic aortic valve assessed by continuous wave Doppler. Mid figure: Pulsed wave spectral 
TD curve with sample volume in the base of the inferioseptal wall showing systolic and 
diastolic mitral annular velocities. Right figure: Off-line colour TD trace analyses with 
systolic and diastolic mitral annular velocities of the base of the inferioseptal and 
anterolateral wall. 
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1.1.3 Ejection fraction versus longitudinal function 
Quantification of LV systolic function has traditionally been based on measurements of 
changes in cavity volumes during systole (i.e. stroke volume and ejection fraction). LVEF is 
the most widely used measurement of LV systolic function and is a key functional and 
prognostic marker of heart disease, due to the huge amount of studies supporting the 
prognostic information and the guidance of therapeutic interventions linked to LVEF. 
However, LVEF may overestimate the myocardial function in small hypertrophic hearts (32), 
has limited reproducibility and is not an optimal indicator of the contractile properties of the 
myocardium (33). 
The concept of the heart functioning as a double pump, with the atrioventricular plane 
as a piston, was described already by Leonardo da Vinci (34). The basis for all measurements 
of longitudinal function is the understanding of the relatively fixed apex and the displacement 
of the atrioventricular plane towards apex during systole. Annular measurements reflect the 
total shortening of the ventricle, and are measurements of global longitudinal function. The 
mitral annular excursion (MAE) was first measured directly by M-mode (35). The correlation 
between MAE and LVEF is strong in dilated ventricles. In normal ventricles, the MAE is 
related to the stroke volume (36). In LV hypertrophy,  MAE is reduced despite preserved 
LVEF and the correlation is poor (37). MAE is also reduced in patients with heart failure and 
preserved ejection fraction (38). The displacement of the atrioventricular plane is influenced 
by the total ventricular size, and smaller ventricles have lower MAE than healthy larger 
ventricles. Thus, variations in MAE are caused by both variations in size and function of the 
heart. Correcting MAE for the heart size has so far only been proven useful in children where 
LV size varies considerably (39).  
The peak velocity of the atrioventricular plane towards apex during systole is another 
measurement of the longitudinal function. The annular velocities can be measured by colour 
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tissue Doppler (TD) from high frame rate colour TD or by pulsed wave spectral TD measured 
at the outer edge of the band-shaped spectrum. By colour TD the mean velocities of the 
regions of interest are assessed (autocorrelation method), which will give lower values 
compared with pulsed wave spectral TD (40) (41). The peak systolic mitral annulus velocity 
(S') occurs early in systole, and is related to LV acceleration. S' has been validated as a 
measurement of global systolic function (42, 43). The correlation of S' with EF is weaker than 
for MAE, which is expected as EF and MAE are end-systolic measurements, reflecting the 
total systolic work (stoke volume) while S' is a peak systolic velocity measurement reflecting 
the peak systolic performance (contraction). S' is reduced in patients with heart failure with 
normal ejection fraction (44).  S' can differentiate between pathologic and physiologic LV 
hypertrophy (43) and has been shown to be a sensitive marker for reduced function in 
mutation positive relatives of patients with manifest hypertrophic cardiomyopathy (45). 
1.1.4 Regional function by deformation imaging 
Deformation imaging is quantitative methods used to assess myocardial global and regional 
deformation, most often used as measurements of systolic function. Visual evaluation of wall 
motion is a robust and quick way to evaluate regional myocardial function, but WMS is semi-
quantitative. With the introduction of tissue Doppler echocardiography in the 1990s, it was 
possible to quantify regional myocardial deformation as strain and strain rate, mainly along 
the long-axis of the left ventricle (18). Semi quantitative assessment of wall shortening by 
colour strain rate imaging was shown to be equivalent to B-mode wall motion scoring by wall 
thickening (20).  
Systolic longitudinal strain is the systolic shortening of a myocardial segment relative 
to the end diastolic length (
0
0
es L
LLS  ), i.e. relative deformation, expressed in percent, with 
negative values indicating shortening. Likewise, circumferential systolic strain is 
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circumferential shortening, and is negative. Transmural (radial) systolic strain is wall 
thickening, and is positive. Strain rate means deformation rate, expressed in s-1. Experimental 
studies have shown that end-systolic strain is highly influenced by afterload, while peak 
systolic strain rate, most often occurring on the early 1/3 of systole, is more closely linked to 
the regional contractile function (46, 47).  However, clinical usefulness of these methods has 
been limited due to problems with noise and artefacts (48). The technique of speckle tracking 
is based on the interference of the reflected ultrasound as well as uneven reflection properties 
of the myocardium, giving rise to a unique irregular random speckled pattern in the 
myocardium. Kernels corresponding to myocardial areas are tracked forwards and backwards 
during the cardiac cycle. By the speckle tracking method it is possible to measure the 
percentage shortening of a myocardial segment during systole (strain), and by temporal 
derivation strain rate can be calculated. Speckle tracking echocardiography has gained more 
widespread acceptance than TD based deformation imaging, mainly because it has been 
implemented with a more user friendly user interface (26). However, definite proof of added 
diagnostic value over conventional wall motion score index is still scarce. In addition, the 
regional speckle tracking values are normally highly influenced by spline smoothing, and 
thus, substantially depended of the MAE, which is a global index of LV performance. In the 
recent versions of commercial speckle tracking software, the smoothing is adjustable, but it 
remains to be proven whether a lower degree of smoothing might increase diagnostic 
accuracy in conditions with regional dysfunction.  
Deformation analyses were developed to assess segmental myocardial function, but 
the average of these segmental data is commonly used to assess global ventricular function. 
Global strain corresponds to displacement of the atrioventricular plane corrected for LV 
length, while global strain rate corresponds to the spatial derivative of myocardial velocity 
(Figure 2). Thus, MAE divided by LV length is a measurement of LV global longitudinal 
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strain. However, normal values differ due to different post processing and because MAE/LV 
length is measured along a straight line while longitudinal strain is measured along a curved 
line. Global average of segmental speckle tracking based longitudinal strain has shown better 
prediction of long term mortality compared with LVEF and WMSI (49). 
 
Figure 2. Strain rate is equal to the velocity gradient (spatial derivative of velocity), and 
strain is the displacement gradient (spatial derivative of displacement). Velocity and 
displacement are global measures (measures the whole ventricle apical to the localization of 
the measurement), while strain and strain rate measures regional deformation. Courtesy: 
Asbjørn Støylen (http://folk.ntnu.no/stoylen). 
 
Cardiac deformation is 3D with longitudinal and circumferential shortening and 
transmural (radial) thickening during systole. With speckle tracking, the different deformation 
components can be approximated, and this has led to a search for “the most sensitive 
direction”. However, the different myocardial layers are tightly connected which indicates 
that the accuracy of the measurement is most crucial for detecting dysfunction regardless of 
which direction being measured. Due to the principle of incompressibility of the myocardium 
the systolic wall thickening has to follow systolic shortening (20, 32). However, concentric 
myocardial hypertrophy will reduce the luminal diameter of the LV, and thus, the percentage 
fractional or radial shortening and ejection fraction will increase (32), even when the 
longitudinal shortening decreases. There is a common misconception that reduced systolic 
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longitudinal function is compensated by increased radial function (32). This is due to the fact 
that longitudinal function is measured in the myocardium, while radial function is measured 
in the cavity (50). 
1.1.5 Three-dimensional echocardiography 
The evolution of 3D echocardiography from slow and labour-intense offline reconstruction to 
real-time volumetric imaging has been one of the most significant developments in ultrasound 
imaging of the last decade. The clinical acceptance of this new tool has broadened 
significantly. A firmly established advantage of 3D compared with 2D echocardiography is 
the improvement in the accuracy and the reproducibility of the evaluation of LV volumes and 
LVEF demonstrated by multiple studies with widely accepted reference techniques, including 
magnetic resonance imaging (MRI) (51, 52). In contrast to 3D echocardiography, 
quantification of chamber volumes by 2D echocardiography is based on assumption of the LV 
shape, but the LV geometry has considerable individual variations particularly in the presence 
of aneurysms, asymmetrical ventricles, or wall motion abnormalities. Errors caused by apical 
foreshortening are also more common in 2D echocardiography. Despite the high correlation 
with the MRI, several studies have reported that 3D echocardiography significantly 
underestimate LV volumes compared with MRI. This may be explained by differences in the 
separation between myocardial tissue and trabeculae of the two imaging techniques (53). 
Three-dimensional echocardiography may also be useful in the assessment of atrial and right 
ventricular volumes and function and the evaluation of LV dyssynchrony (53). 
 The standard planes of 2D echocardiography do not encompass the entire left 
ventricle, resulting in a potential risk of missing deformation abnormalities between the 
planes. The ability of 3D echocardiography to cover the entire heart in one data set from 
which the ventricle can be viewed in any plane orientation, suggests that 3D 
echocardiography have the potential to overcome errors caused by misalignment and out-of-
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plane motion in 2D wall motion analysis. Three-dimensional echocardiography can display 
multiple 2D short-axis slices simultaneously, and automated tracking of the long-axis motion 
can reduce out-of-plane motion, which may cause misinterpretations in 2D analysis. So far 
there is little evidence of incremental diagnostic value of 3D wall motion analysis compared 
with deformation imaging by 2D echocardiography (53). Therefore the aim of paper 4 was to 
compare the accuracy of 3D and 2D echocardiography in the evaluation of the global and 
regional myocardial function following acute MI. 
 Recent improvements in 3D matrix array transducers have enabled real-time 
visualization of valves and subvalvular anatomic features with improved resolution and more 
realistic imaging of valves. Real-time 3D transesophageal echocardiography plays an 
increasingly important role in the management of valvular heart disease and can be used in the 
intraoperative evaluation of patients undergoing mitral valve repair (54). Three-dimensional 
transesophageal echocardiography has been shown to be highly accurate and reproducible in 
localizing prolapsing segments of the mitral valve (55), and the determination of aortic valve 
area by the continuity equation is more accurate when 2D LVOT measurements are 
substituted by 3D planimetered LVOT measurements (56). In prosthetic valve endocarditis, 
3D transesophageal echocardiography has been shown to correlate well with surgical 
findings, may identify additional vegetations not seen on 2D, and can assist in differentiating 
vegetations from loose suture material (57). However, because of frame rate limitations in 3D 
echocardiography 2D echocardiography remains superior for the identification of small 
mobile vegetations (54).  
1.2 Cardiac magnetic resonance imaging  
Cardiac MRI is an attractive imaging modality due to its non-radiation nature and its high 
image quality. The availability of the method has increased, and cardiac MRI is now an 
important tool in the guidance of therapy in many patients. 
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1.2.1 Left ventricular function by cardiac MRI 
Cardiac MRI is generally recognized as the most accurate and reproducible technique for 
assessing LV volume, mass and ejection fraction owing to its high spatial resolution, excellent 
signal-to-noise ratio, and the possibility to acquire images in any orientation of the heart. 
Therefore cardiac MRI is considered as the reference standard for these purposes (58-60), 
although definite proofs of incremental prognostic value compared with LVEF by 
echocardiography are still lacking (61). Cardiac MRI will continue to be an invaluable 
research tool, and sample sizes can be smaller with MRI than with echocardiography for 
assessing changes in ventricular volumes, mass, and function in the evaluation of 
pharmacologic treatment in heart disease (62). Cardiac MRI examinations should follow a 
protocol that includes assessment of left and right ventricular volumes and function as well as 
evaluation of wall thickness, valvular function, atrial dimensions, the pericardium, and 
myocardial tissue characterization.  
1.2.2 Cardiac MRI in ischemic heart disease 
The development of late enhancement magnetic resonance imaging (LE-MRI) has offered the 
opportunity to characterise the myocardial tissue in an entirely new way. By using the 
extracellular contrast agent gadolinium, LE-MRI takes advantage of the delayed wash-in and 
wash-out of contrast in areas with increased extracellular volume; i.e. scar or fibrosis. In 
addition, an inversion-recovery sequence magnifies the difference between healthy and 
infarcted tissue. This gives a method with high accuracy and reproducibility, and LE-MRI is 
established as the reference standard for the quantification of myocardial scars (60, 63). The 
pattern of hyperenhancement can provide additional information about etiology of the scars. 
In coronary artery disease the expansion of the ischemic injury is starting from the 
subendocardium and progressing toward the epicardium located in a region that is consistent 
with a perfusion territory of an epicardial coronary artery (64) (Figure 3). Subendocardial 
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hyperenhancement may also be seen in amyloidosis, systemic sclerosis and after cardiac 
transplantation, but in these conditions the hyperenhancement does not correspond to the 
perfusion territories of the epicardial coronary arteries (59). Midwall or epicardial 
hyperenhancement is common in myocarditis, hypertrophic cardiomyopathy and Fabry′s 
disease (59).  
 
Figure 3. Scar visualization by late enhancement magnetic resonance imaging. White 
hyperenhanced areas in the septal and anterior wall corresponding to the left anterior 
descending coronary artery. The expansion of the ischemic injury is starting from the 
subendocardium and progressing almost to the epicardium, indicating transmural infarction 
(segmental infarct volume fraction >50%). 
Hibernating myocardium refers to a dynamic condition of chronic abnormally 
contracting myocardium, with function that improves after revascularization. Low-dose 
dobutamine stress MRI is accurate in the assessment of contractile reserve and in the 
detection of hibernating myocardium. However, wall thickening in cardiac MRI may be 
difficult to quantify due to the effects of trabeculae that are merging in end-systole, and 
incremental prognostic value compared with radionuclide methods and dobutamine stress 
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echocardiography needs to be confirmed. LE-MRI can determine the transmural extent of scar 
and the remaining viable rim. Increasing segmental infarct transmurality assessed by LE-MRI 
showed a gradual decreasing likelihood of response to revascularisation (65). However, the 
prediction of recovery is not accurate in the segments with 25-75% infarction.  
1.3  Reproducibility in medical imaging 
Reproducibility is the degree of agreement between measurements or observations preferably 
conducted in different locations by different observers. Reproducibility is part of the precision 
of a test method. Repeatability or test-retest reliability is often defined as 
the variation in measurements taken by a single person or instrument on the same item and 
under the same conditions (66). 
Accuracy and reproducibility of echocardiographic measurements is essential for 
addressing correct diagnosis, decision making and reduce the frequency of unnecessary, 
repeated examinations. Reproducibility is also fundamental in cardiac research as 
echocardiography is widely applied in clinical trials in order to identify potential mechanisms 
of clinical end-points or to assess surrogate end-points.  
1.3.1 Estimation of reproducibility in medical imaging 
The reproducibility is often reported as different variants of correlation coefficients. 
The Pearson correlation coefficient is sometimes misapplied in agreement studies. It describes 
the closeness of the linear relationship between two variables, but the test is potentially 
misleading as there may be a strong correlation between two variables but poor agreement, 
and there might be an undetected systematic error. The intraclass correlation coefficient (ICC) 
and Lin’s concordance correlation coefficient avoid the problem of linear relationship being 
mistaken for agreement. The intraclass correlation coefficient is centred and scaled using a 
pooled mean and SD, whereas the Pearson correlation coefficient is centred and scaled by its 
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own mean and SD. The Lin’s concordance correlation coefficient assesses the closeness of the 
data about the line of best fit in the scatter plot by taking into account how far the line of best 
fit is to the line of equality. However, all correlation coefficients are highly influenced by the 
range of measurements, and the correlation coefficients tell us little about the size of errors 
between the methods. If the range of measurements is wide, the correlation coefficients might 
be high despite moderate agreement between the methods. If the range of measurements is 
small, the correlation coefficients might be low despite moderate or good agreement between 
the methods. Thus, comparing correlation coefficients of different study populations is totally 
misleading. Furthermore, the correlation coefficients may be difficult to interpret, as 
consensus regarding clinical acceptable levels is lacking (67).  
Bland and Altman recognised the limitations of using correlation coefficients in the 
clinical comparison of the agreement between two measurement methods, and in their 
landmark paper they elegantly describe why two methods may have strong correlation but 
poor agreement (66). They introduced the “95% limits of agreement” which gives a much 
better description on how much two methods differ and whether two methods may be used 
interchangeably or a new method may replace an old method. Their approach has been used 
extensively for the assessment of agreement between two methods and repeated 
measurements of a single measurement by one or two observers. The method can easily be 
interpreted in a clinical context as 95 percent of repeated measurements are expected to be 
within the interval given by the 95% limits of agreement. If the difference between two 
methods is not significantly different from zero, the 95% limits of agreement is equivalent to 
the coefficient of repeatability (66).  
The 95% limits of agreement is based on a linear relationship between the errors, but 
echocardiographic measurements may have errors that are proportional to the magnitude, 
especially when they are collected over a large physiological range. This can be overcome by 
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logarithmic transformation, which gives a different coefficient of repeatability at different 
measurement magnitudes (66, 68). An alternative approach is to divide the error with the 
mean to get the mean absolute error, which is a dimensionless ratio. The percentage error is 
calculated as the absolute difference between the two sets of observations, divided by the 
mean of the observations. Expressing the error in per cent allows direct comparisons between 
methods with different measurement units and is frequently used in the assessment of 
reproducibility in cardiac imaging (69-71). A similar approach is to calculate the coefficient 
of variation as the within-subject SD divided by the mean of the observations. When only two 
repeated measurements are measured, the coefficient of variation is directly proportional to 
the mean error, and their relation is given by the following equations:  
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x
xx
n
x
SDCOV
n
i
i
2
1
)(
1
1   
¦
   Eq. 4: COV
x
xx
Error u  2% 21  
 
The mean error is more easily interpreted as it directly describes the percentage difference 
between two methods. The coefficient of variation is in contrast to the mean error also 
possible to calculate when more than two repeated measurements are measured.  
For non-parametric data, different statistics are required. A commonly used and valid 
statistic with categorical data is Cohen’s kappa coefficient. The kappa coefficient has the 
added advantage that is takes into account the agreement occurring by chance. However, the 
kappa coefficient has some of the same limitations as the intraclass correlation coefficient. A 
non-parametric variant of the limits of agreement method has been described, where data can 
be ranked with a range of data reported within centiles (72). If 95th percentiles are used, 
including presentation on a difference plot, this approach resembles 95% limits of agreement.  
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1.4 Contraction and contractility of the left ventricle 
1.4.1 Different phases during systole 
The opening and the closure of the cardiac valves divide the cardiac cycle into different 
phases. The phases of the cardiac cycle can also be described by the volume changes and the 
pressure changes during the heart cycle (50). The flow is a result of the pressure differences, 
and the volume changes are a direct result of flow (the volume is the integrated flow rate). 
The isovolumic contraction phase is the first part of systole, and ventricular contraction after 
mitral valve closure is characterised by increase in tension and pressure, but no volume 
changes (no flow in or out of the ventricle), although there may be small changes in 
ventricular shape. In the ejection phase, there is ejection of the stroke volume (flow), and a 
corresponding decrease in ventricular volume (Figure 4A). The ejection phase can be divided 
into the rapid ejection during the last part of myocardial contraction and the reduced ejection 
during the first part of relaxation, both belonging to the ventricular systole (Figure 4B). In the 
last part of ejection there is decrease of myocardial tension - relaxation, but continuing 
outflow of blood and volume decrease due to the inertia of blood.  In the isovolumic 
relaxation phase, which is the first part of diastole, there is decrease in tension, but no volume 
change. In the early filling phase, there is continuing ventricular pressure decrease and filling 
flow, and a corresponding increase of ventricular volume. In the subsequent diastasis, there is 
little or no flow and volume change. In the last part of diastole, the late filling phase, there is 
flow into the ventricle and increase in ventricular volume due to atrial contraction. 
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Figure 4A      Figure 4B 
Top, Ventricular volume curve, during the different 
phases of the cardiac cycle. Below, composite Doppler 
flow velocity curve showing both LVOT outflow and 
mitral inflow to the left ventricle. The flow velocity curve 
is an approximation to flow rate, and hence, similar to 
the temporal derivative of the volume curve, or, 
conversely, the volume changes are the integrated flow 
rate. The isovolumic phases are exaggerated.  
Courtesy: Asbjørn Støylen (http://folk.ntnu.no/stoylen). 
 
The Wiggers cycle. The pressure changes are indications of 
myocardial tension. The decline in tension (i.e. relaxation of 
the myocardium) starts close to mid ejection, but the ejection 
of flow and volume reduction still continues. Thus the 
ejection phase can be divided into the rapid ejection during 
the last part of myocardial contraction and the reduced 
ejection during the first part of relaxation, but both ejection 
phases and the isovolumic contraction belong to the 
ventricular systole. After: McGill Faculty of Medicine e-
curriculum (http://alexandria.healthlibrary.ca). 
 
 
1.4.2 Estimation of contraction and contractility in medical imaging 
The assessment of LV dysfunction is a frequent indication for echocardiography. However, 
LV dysfunction is a general and non-specific entity that is defined depending on the context 
(33). For instance are the LVEF and the diastolic assessment highly dependent on loading and 
may produce abnormal results under unusual loading conditions. Although the value of LVEF 
for assessing LV dysfunction is unquestionable, the referring clinician is often also requesting 
an assessment of the nature of the underlying myocardial tissue. Intrinsic cardiac function 
implies the assessment of true contractility (73). True contractility of the myocardium is 
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currently not measurable non-invasively in clinical practice (33), but detecting the best non-
invasive surrogate for true contractility has been an important task in cardiac research for 
decades.  
Contraction is generation of tension, and contractility is the intrinsic ability of the 
muscle to generate force independently of load (50). When an isolated myocyte is under no 
influence of load, the generated tension corresponds to shortening and the contraction equals 
contractility. In the intact heart, there is external load, and deformation is a consequence of 
tension and load. If the load is greater than the tension developed, the contraction is isometric, 
i.e. contraction with tension development without shortening. If the tension exceeds the load 
(and the load is constant) the contraction is isotonic (shortening at constant load).  In the 
heart, the load and the tension changes during the cardiac cycle and causing a mix between 
isometric and isotonic contraction. 
During the systole, there is active contraction only during isovolumic contraction and 
the first part of the ejection period (until peak ventricular pressure). Thus, a considerable part 
of the energy from myocyte contraction is used to build up the ventricular pressure from the 
low filling pressures of the left atrium to the high ejection pressures of the aorta. Therefore the 
ejection do not correspond to myocyte contraction, and force development (contraction of the 
myocytes) which generates sufficient pressure to open the cardiac valves should be 
distinguished from deformation (shortening of the myocytes) which gives rise to the actual 
volume ejection. In the last part of ejection, there is myocyte relaxation, but still flow and 
volume reduction due to the inertia of the blood. Cardiac imaging can visualise wall motion, 
wall-deformation, cavity deformation or flow but only a part of myocyte contraction. 
It is still questionable whether some echocardiographic indices are more closely 
related to contraction than others, but in an experimental study, beta blocker and dobutamine, 
strain rate was most closely related to the maximal first derivative of LV pressure (peak 
 30 
dP/dt), while strain and displacement were more closely related to stroke volume and EF (47). 
Myocyte contraction occurs in the first part of systole, which corresponds well to the timing 
of the echocardiographic peak systolic velocity indices like peak systolic annulus tissue 
velocities, peak ejection velocity and peak systolic strain rate. These measurements may also 
be less load dependent, as maximum afterload is reached later in systole. Peak velocity is also 
related to acceleration, which is a direct measure of force, and thus to contraction. In contrast 
to force development, deformation and volume ejection continue until the end of systole, and 
end-systolic echocardiographic indices like ejection fraction, fractional shortening, systolic 
mitral annulus displacement, global strain and the ejection velocity time integral are 
measurements of the total work performed by the left ventricle during ejection (47).  
1.5 Myocardial infarction 
1.5.1 LV function and prognosis after acute myocardial infarction  
The goal of risk stratification after MI is to identify patients whose outcomes can be improved 
through specific medical interventions. Previous studies have established LVEF as an 
important predictor for mortality with therapeutic implications in patients with coronary artery 
disease (74). In patients with coronary artery disease and severely depressed LV function, the 
mortality is high and progressive pump failure is the main cause of death (74). In patients with 
coronary artery disease and preserved or moderately depressed LVEF the overall annual 
mortality ranges from 5% to 15%, with a relatively high percentage of sudden cardiac deaths 
(75, 76). Although the precise cause of sudden cardiac deaths may be uncertain, it has been 
demonstrated that scar tissue may serve as a substrate for lethal arrhythmias (77). 
Quantification of scar tissue gives incremental prognostic value beyond LVEF and may be 
superior to LVEF for prediction of all-cause mortality in patients with preserved or 
moderately depressed LV function (78, 79).  
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Myocardial ischemia rapidly impairs contractile function, which may persist for 
several hours after reperfusion (myocardial stunning), or might lead to chronic dysfunction 
even when perfusion are re-established. The pathophysiological substrate of chronic 
dysfunction is heterogeneous, varying from predominantly hibernating myocardium to 
irreversible scarring. Hibernating myocardium is most commonly defined as dysfunctional but 
viable myocardium with the potential to regain contractility after revascularization (80). This 
definition is retrospective and thus not useful for clinical decision making. Patients with 
hibernating myocardium have been shown to have a significant survival advantage following 
revascularization (60, 81). In fact, the meta-analysis by Allman (82) seemed to show no 
prognostic benefit of revascularisation at all, if there was no viability. However, in a recently 
published substudy of the STICH trial, myocardial viability assessed by single photon 
emission computed tomography or dobutamine echocardiography, did not identify patients 
with survival benefit from coronary arterial bypass grafting (83). The study has several 
important limitations (84), but it questions the benefit of viability imaging and whether 
surgery could be refused on the basis of imaging alone. Other studies have indicated that 
assessment of myocardial viability is superior to regional scar quantification by LE-MRI in 
prediction of improvement in myocardial dysfunction after revascularization (85, 86).   
1.5.2 Quantification of myocardial infarct size 
Evaluation of the regional myocardial function following acute MI is of major importance as 
the morbidity and mortality are closely related to infarct size and location (60). Prognosis is 
progressively worse with increasing amounts of scar, and scar quantification by LE-MRI may 
be a stronger predictor of adverse clinical outcome than LVEF and volumes in the presence of 
healed myocardial infarctions (87-89), but LE-MRI is less available than echocardiography in 
most clinical settings. Echocardiographic measurements of the LV function have been 
extensively validated in patients with MI (20, 90, 91), and a good agreement with LE-MRI 
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has been demonstrated (92, 93). However, most echocardiographic methods are 
measurements of global LV function, where the degree of function reduction may serve as an 
indirect estimate of infarct size. In paper 3 we present a new method for direct quantification 
of infarct size, and the accuracy of echocardiography in predicting myocardial infarct size is 
one of the aims of this thesis. 
The transmural extent of scar assessed by LE-MRI can predict the likelihood of 
functional recovery after revascularization. The initial landmark study by Kim et al showed a 
gradual decreasing likelihood of response to revascularisation with increasing segmental 
infarct transmurality (65). Scars with <25% transmural extent had 72% likelihood of 
functional recovery, whereas scars with >75% transmural extent had <2% likelihood of 
functional recovery. However, in the large group of segments with 25-75% infarction, the 
prediction of recovery was not very accurate. In a study by Kelle et al (94) the presence of 
scar on LE-MRI images was more accurate for predicting events than hibernating 
myocardium assessed by low-dose stress MRI in patients with <6 scarred segments. 
Conversely, hibernating myocardium assessed by low-dose stress MRI was a better predictor 
of events than scar tissue on LE-MRI in patients with >6 scarred segments (94). In a recent 
review paper regarding the management of ischemic cardiomyopathy, combined scar imaging 
and contractile reserve assessment by MRI is suggested as a future gold standard (60). 
However the costs are high and the evidence is sparse for recommending these examinations 
in everyday clinical practice, and a substantial part of the MI patients has contraindications to 
MRI. Echocardiography is widely available, harmless, fast, relatively cheap, and therefore 
more suitable as first line imaging modality. It remains to be proven whether recent 
technological improvements in echocardiography provide increased diagnostic accuracy. 
Therefore the aim of paper 3 and 4 was to compare the accuracy of new and traditional 
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echocardiographic methods in the evaluation of the global and regional myocardial function 
following acute MI. 
Many clinicians use values of biomarkers to provide a rough estimate of infarct size. 
Recent data suggest that peak cardiac troponin T values or the 72 to 96 hour values correlate 
well with infarct size by LE-MRI (95-97). The slope of the relationship is different with and 
without reperfusion as reperfusion leads to an earlier and higher maximum. The correlation is 
less robust with NSTEMI than with STEMI (95). However, it has been suggested that patients 
with small infarcts have different cardiac troponin T release time curves than patients with 
large myocardial infarction. Therefore, it cannot be excluded that in patients with NSTEMI, 
an earlier cardiac troponin T sampling time point would result in better correlation with 
infarct size by LE-MRI. Nonetheless, correlations of cardiac troponins in these studies are 
better than the correlations reported for creatine kinase-MB and N-terminal brain-type 
natriuretic peptide (95, 96). The cardiac troponin T value after 96 hours has been suggested as 
the best single-point value and was as effectively as the peak cardiac troponin T and the areas 
under the receiver operating characteristic curves (AUC) of cardiac troponin T over 96 hours 
(95). For the latter, it is reasonable to speculate that performance of cumulative measurements 
could be improved by expansion of serial measurements beyond 96 hours. However, 
prolongation of sampling is likely to reduce the attractiveness and acceptance of the method. 
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2 Aims 
2.1 General aims 
The overall aim of the thesis is to compare new and traditional ultrasound methodology in the 
assessment of systolic function during inotropic alterations and after recent MI.  
2.2 Specific aims 
1) To study and compare the reproducibility of new and conventional measurements of the 
LV global and regional function, and to test whether the reproducibility data based on 
repeated measurements of single datasets underestimate the more clinically relevant inter-
observer reproducibility based on separate recordings. 
2) To compare the ability of different echocardiographic methods in detecting contraction 
changes of the LV, and to test whether the peak systolic velocity indices better reflect changes 
in contraction compared with the end systolic indices. 
3) To validate a new method for direct quantification of infarct size based on area 
measurement by tissue Doppler based colour coded strain rate data and wall motion analysis, 
and to test whether this method gives higher diagnostic accuracy compared with other 
echocardiographic techniques. 
4) To compare the diagnostic accuracy of 3D wall motion analysis, 3D speckle tracking 
echocardiography and 2D echocardiography in patients with recent myocardial infarctions, 
using LE-MRI as reference method in order to test whether 3D echocardiography gives added 
diagnostic value in this population. 
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3 Study population characteristics 
3.1 The reproducibility study (study 1) 
The study population consisted of ten (7 men and 3 women) healthy volunteers (30 ± 6 years). 
The subjects were free from medications, known cardiovascular disease, structural heart 
disease, diabetes or hypertension. None were excluded due to inadequate echocardiographic 
images.  
3.2 The contraction study (study 2) 
The study population consisted of 33 (25 males and 8 women) healthy volunteers (20-32 
years). Thirty subjects were medical students. Two subjects were recruited among the staff of 
the faculty of medicine, and one of the volunteers was an engineer student. The subjects were 
free from medications, known cardiovascular disease, structural heart disease, diabetes or 
hypertension. None were excluded due to inadequate echocardiographic images. Table 1 
shows the basic characteristics of the study population. 
Table 1 Characteristics of the study population of study 2. 
 
 
 
 
 
 
 
 
 
Variable Mean (SD) 
Age (years) 25 (2.9) 
Height (cm) 179 (6.5) 
Weight (kg) 75 (12) 
BMI (kg/m2) 23 (3) 
BSA (m2) 1.9 (0.2) 
LV mass (g) 180 (27) 
LV volume (ml) 134 (27) 
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Table 1: The parameters are displayed as mean (standard deviation). BMI = body mass 
index; BSA = body surface area; LV = left ventricular. LV mass and volume were obtained 
from real-time 3D echocardiography. 
 
3.3 The patients with recent myocardial infarction (study 3 and 4) 
The final infarct population of study three and four consisted of 58 patients with first time MI. 
None were excluded due to inadequate echocardiographic images. Forty six (79%) had 
STEMI, while 12 (21 %) had NSTEMI. Coronary angiography identified a coronary culprit 
lesion in all patients. Percutaneous coronary intervention (PCI) of the culprit coronary lesion 
was performed during the hospital stay in all patients except three patients in whom the 
defined culprit lesion was not amenable to PCI. The median time from onset of symptoms to 
PCI was 3.0 hours (range 0.6-140 hours). PCI was performed within ≤ six hours from onset of 
symptoms in 39 patients. Additional patient characteristics are listed in Table 2.  
3.4 The sex and age matched healthy volunteers (study 3 and 4) 
The control group of study three and four consisted of 35 age- and sex-matched participants in 
the Echocardiography in the Nord-Trøndelag Health Survey (HUNT). None were excluded 
due to inadequate echocardiographic images. Patient characteristics are listed in Table 2.  
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Table 2 Patient characteristics, risk factors, angiographic findings and medications of 
study 3 and 4. 
 Infarct Size >12% 
(n=25) 
Infarct Size <12% 
(n=33) 
Healthy controls 
(n=35) 
LE-MRI infarct size 
(infarct volume fraction) 
19.5 ± 5.7% * 5.3 ± 3.2% not available 
Age, years 
 
56.7 ± 13.6 54.9 ± 12.9 56.9 ± 13.0 
BMI, kg/m2 
 
26.1 ± 6.0 25.4 ± 5.4 26.1 ± 5.2 
Male sex, n (%) 
 
19 (76) 25 (76) 28 (80) 
Heart rate, bpm  
 
64 (11) 60 (11) † 67 (11) 
Current smoker, n (%) 
 
12 (48) 17 (52) - 
Creatinine, μmol/L 
 
68.5 1 ± 7.1 ‡ 70.5 ± 17.2 † 88.0 ± 19.1 
Peak Troponin T, μg/L 
 
7.7 ± 5.7 * 3.2 ± 2.4  not available 
Hypertension, n (%) 
 
5 (20) 5 (15) - 
Diabetes mellitus, n (%) 
 
4 (16) 2 (6) - 
STEMI, n (%) 
 
22 (88) 24 (73) - 
Single vessel disease, n (%) 
 
14 (56) 25 (76) not available 
LAD culprit, n (%) 
 
10 (40) 13 (39) - 
CX culprit, n (%) 
 
7 (28) 6 (18) - 
RCA culprit, n (%) 
 
8 (32) 14 (42) - 
Aspirin, n (%) 
 
25 (100) 33 (100) - 
Clopidogrel, n (%) 
 
25 (100) 33 (100) - 
Beta-blocker, n (%)  
 
23 (92) 29 (88) - 
Statin, n (%) 
 
25 (100) 33 (100) - 
ACEi or ARB, n (%) 
 
7 (28) 8 (24) - 
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Table 2: Continuous variables displayed as mean ± SD. Categorical variables are displayed 
as numbers (percentage). * P<0.001 for large MIs vs. small MIs; † P<0.05 for small MIs vs. 
healthy controls; ‡ P<0.001 for large MIs vs. healthy controls. Abbreviations: ACEi = 
angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor blockers; bpm = 
beats per minute; BMI = body mass index; LE-MRI = late enhancement magnetic resonance 
imaging; CX = circumflex coronary artery; LAD = left anterior descending coronary artery; 
RCA = right coronary artery; STEMI = ST-segment–elevation myocardial infarction. 
4 Methods  
4.1 Inclusion and exclusion  
4.1.1 The reproducibility study (study 1)  
In this echocardiographic study 10 healthy volunteers were prospectively recruited among the 
staff at the Department of Circulation and Medical Imaging at the Norwegian University. 
Validation of the normality of the study population was performed by careful medical history 
and examinations by the physician echocardiographers (AT and HD).  
4.1.2 The contraction study (study 2) 
The participants were recruited after local advertisement broadcasted on the main website of 
the faculty of medicine. Healthy students free from medications were encouraged to contact 
the responsible investigator (AT) by e-mail. Three candidates refused to participate after more 
detailed information of the study protocol. Written informed consent was obtained from the 
final study population of 33 (25 males and 8 women) healthy volunteers (20-32 years). 
Validation of the normality was performed by careful medical history and examinations 
including electrocardiogram and echocardiogram at rest. None were excluded due to 
inadequate echocardiographic image quality. 
 39 
4.1.3 The patients with recent myocardial infarction (study 3 and 4) 
The study was conducted at St Olavs University Hospital, which is a tertiary coronary care 
centre in Trondheim, Norway. The responsible investigator (AT) consecutively considered all 
the discharged patients at the department of cardiology from April 2008 to June 2009 for 
possible participation, by reading the discharge summaries. Exclusion criteria were peak 
cardiac troponin T measurement <0.5 μg/L, prior MI, bundle-branch block with QRS duration 
>130 ms, significant valvular disease, previous heart surgery, age above 75 years, extensive 
co-morbidity with short life expectancy, chronic atrial fibrillation and contraindications to 
LE-MRI. All patients with estimated glomerular filtration rate <60 ml/min per 1.73m2 or 
temporary increase in creatinine during the hospital stay were excluded form the study. 
Patients who had >100 kilometers driving distance to the hospital were also excluded. Of the 
82 patients eligible for participation, we were able to reach 77 patients by mail. After reading 
the informed consent and receiving further information by phone, six patients denied 
participating due to fear of discomfort during the MRI examination. Thus, 71 consecutive 
patients with documented first time non–ST-segment–elevation myocardial infarction 
(NSTEMI) or ST-segment–elevation myocardial infarction (STEMI) and peak cardiac 
troponin T measurement >0.5 μg/L were prospectively enrolled from April 2008 to June 
2009. No patients were excluded because of impaired echocardiographic image quality. 
Written informed consent was obtained. Five patients were excluded because they were not 
able to complete the LE-MRI examinations due to claustrophobia. Another eight patients were 
excluded due to sub-optimal LE-MRI image quality. Thus the final patient population was 58. 
4.1.4 The sex and age matched healthy volunteers (study 3 and 4) 
 
In the third wave of the HUNT Study a total of 93,210 people were invited, and 50,839 (54%) 
participated from autumn 2006 to June 2008. The selection of healthy participants was based 
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on the self-administered main questionnaire of the HUNT Study, where participants were not 
eligible if they answered ‘Yes’ to any of the questions about ‘having’ or ‘ever had’ 
cardiovascular disease, hypertension or diabetes. Participants were then selected by 
randomization. Validation of the normality was performed by careful medical history and 
examinations by the physician echocardiographer (HD). After exclusion of 30 subjects due to 
significant pathology on echocardiography, electrocardiogram or clinical examination, the 
final study population consisted of 1266 subjects in the HUNT echocardiography study.  No 
patients were excluded because of impaired echocardiographic image quality. Written 
informed consent was obtained. From this study population, 35 subjects matched for age and 
sex with the infarct population of study three and four, were randomly selected as healthy 
control group. 
4.2 Study design 
4.2.1 The reproducibility study (study 1)  
Two experienced physician echocardiographers (AT and HD), blinded to each other’s 
recordings, performed separate complete echocardiographic examinations on all the 
participants (20 examinations in total). The recordings on the same subject were separated by 
a time interval of approximately 30 minutes. Both echocardiographers analysed all 
measurements. Inter-observer reproducibility was defined as the reproducibility calculated by 
separate recordings. Inter-analyser reproducibility was defined as the reproducibility 
calculated by the two echocardiographers’ analyses of the same set of recordings. Intra-
analyser reproducibility was defined as the reproducibility calculated by one of the 
echocardiographers reanalyses of his own recordings. The reanalyses were done in random 
order after a period of approximately three weeks.  In all, 20 examinations and 50 analyses 
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were obtained. The study was approved by the Regional Committee for Medical Research 
Ethics, and conducted according to the second Helsinki Declaration.  
4.2.2 The contraction study (study 2) 
All examinations were conducted by one experienced physician echocardiographer (AT). A 
complete echo/Doppler study at rest was performed in all the participants. Low-dose 
dobutamine stress echocardiography was performed in 13 subjects. Both low-dose 
dobutamine stress echocardiography and echocardiography after intravenous administration 
of metoprolol were performed in seven subjects. Echocardiography after intravenous 
administration of metoprolol was performed on 13 subjects. In total 20 paired rest-dobutamine 
recordings and 20 paired rest-metoprolol recordings were obtained and the subsequent 
measurements were categorised into three contractile states: beta-blocker, rest or dobutamine. 
Dobutamine was initially infused at 5 mcg/kg/min for three minutes, before the 
infusion rate was increased to 10 mcg/kg/min. The recordings were obtained after additional 
three minutes of continuously infusion of 10 mcg/kg/min. dobutamine (steady state). All the 
analyses were based on apical recordings, which were obtained in less than one minute for 
each contractile state. For the beta-blocker study, 15 mg of metoprolol was injected over 10 
minutes, and a new complete echo/Doppler study started 10 minutes after the last injection of 
metoprolol. Thus, for those who received both dobutamine and metoprolol, the recordings 
after infusion of metoprolol started more than 20 minutes after the infusion of dobutamine 
was ended.  
 Recordings of the 20 subjects were compared during resting conditions and under 
influence of dobutamine (paired recordings). Correspondingly, recordings of the 20 subjects 
(with 7 overlapping the dobutamine group) were compared during resting conditions and 
under influence of metoprolol (paired recordings). All participants completed their pre-
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specified protocol. The study was approved by the Regional Committee for Medical Research 
Ethics, and conducted according to the second Helsinki Declaration.  
4.2.3 The infarction studies (study 3 and 4) 
Echocardiograms were performed within three hours before or after the LE-MRI 
examinations and in average 31 ± 11 days after the index MI. Different indices of LV global 
and regional function were obtained from the echocardiographic recordings of the patients 
and healthy controls. LE-MRI was used as a reference method, but the control group was not 
examined by LE-MRI and their infarction size was assumed to be 0%. The correlations 
between global and segmental percentage infarct volume fraction assessed by LE-MRI and 
each global and segmental echocardiographic index were calculated.  
The study population was divided in three; healthy controls, patients with infarct size 
<12%, and patients with infarct size >12%. Furthermore, segments with percentage infarct 
volume fraction <1% were classified as not infarcted, segments with percentage infarct 
volume fraction >1% were classified as infarcted, and segments with percentage infarct 
volume fraction >50% were classified as transmurally infarcted. AUC of each 
echocardiographic method for identification of small MI, large MI, infarcted segments, and 
transmurally infarcted segments were calculated. Thus, study three and four compared 
different echocardiographic methods in the assessment of global and regional LV function in 
patients with recent MI, using LE-MRI as reference method. In study three we tested out 
whether a new method for direct quantification of infarct size based on area measurement by 
TD based colour coded SRs data corrected by visual wall motion analysis gave incremental 
diagnostic value compared with other 2D echocardiographic methods. In study four we tested 
whether 3D dynamic multi-slice echocardiography and 3D speckle gave incremental 
diagnostic value compared with 2D echocardiography. The studies were approved by the 
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Regional Committee for Medical Research Ethics, and conducted according to the second 
Helsinki Declaration.  
4.3 Echocardiographic acquisition and analysis 
 
4.3.1 Echocardiographic image acquisition 
In study one all the participants were examined with a Vivid 7 scanner (GE Vingmed, Horten, 
Norway) with a phased-array (M3S) transducer. All participants in study two and 46 patients 
and the healthy controls in study three and four were examined with a Vivid 7 scanner with a 
M3S transducer for the 2D recordings and a matrix-array (3V) transducer for the 3D 
recordings. Fourteen patients in study three and four were examined with a E9 scanner (GE 
Vingmed, Horten, Norway) with a M3S transducer for the 2D recordings and a 3V transducer 
for the 3D recordings. 
All the participants in the four studies were examined in the left lateral decubitus 
position. The recordings were obtained during quiet respiration or breath-hold. Three 
consecutive cycles in B-mode acquisitions and colour tissue Doppler mode were recorded 
from the three apical views (4-chamber, 2-chamber and long-axis), and three consecutive 
cycles were recorded in B-mode acquisitions from three parasternal views (mitral valve, 
papillary muscle, and apical short-axis planes). In study one and two colour tissue Doppler 
acquisitions were recorded at a mean frame rate of 110 s-1, and the B-mode recordings were 
recorded at a mean frame rate of 44 s-1 in study one and a mean frame rate of 50 s-1 in study 
two. In study three and four colour tissue Doppler acquisitions were recorded at a mean frame 
rate of 123 s-1, and the B-mode recordings were recorded with a mean frame rate 61 s-1.  
Pulsed wave Doppler mitral flow velocities were recorded from the apical four-
chamber view with the sample volume between the leaflet tips. The left ventricular outflow 
tract (LVOT) velocity was recorded from the apical five-chamber view with the sample 
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volume positioned about five mm proximal to the aortic valve. Spectral TD mitral annular 
velocities were acquired with a 6 mm sample volume positioned at the base of the septal, 
lateral, inferior and anterior walls. Recording for isovolumic relaxation time measurement 
was obtained by simultaneous recording of the aortic and mitral flows. Pulmonary venous 
flow velocities were recorded with the sample volume approximately one cm into the right 
upper pulmonary vein.  
Real-time 3D echocardiography recordings were preformed immediately after the 2D 
examination. From the apical approach four to six consecutive ECG-gated subvolumes were 
acquired during end-expiratory apnoea to generate full volume data sets (mean frame rate 26 
s-1). Care was taken to encompass the entire LV cavity and, if unsatisfactory, the data set was 
re-acquired (98). All echocardiographic data were stored digitally and analyzed subsequently. 
4.3.2 Analysis of B-mode and Doppler echocardiography 
LV volumes and LVEF were measured by biplane Simpson's rule from the apical four- and 
two-chamber views (98). End-diastolic volume was measured at the time of mitral valve 
closure, and end-systolic volume was measured on the image with the smallest LV cavity. LV 
internal end-diastolic and end-systolic dimensions, the inter ventricular septal wall thickness, 
and the posterior wall thickness were measured perpendicular to the long axis of the ventricle 
at the mitral valve leaflet tips in the parasternal long-axis view, using anatomical M-mode 
echocardiography. The fractional shortening of the myocardium in short axis was calculated 
as the difference between the LV internal end-diastolic and end-systolic dimension divided by 
the LV internal end-diastolic dimension. LVEF was also obtained from the 3D recordings 
(four-dimensional auto LV quantification, version BT11, GE Vingmed Ultrasound, Horten, 
Norway). End-diastolic and end-systolic volumes were measured after manual alignment 
followed by automatic detection of endocardial surface, which was manually adjusted by 
placing as many additional points as needed in three dimensions at both end-diastole and end-
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systole. Finally the automatically detected epicardial borders were manually adjusted in three 
dimensions at end-diastole in order to calculate LV mass.  
The mitral flow early diastolic filling velocity (E), late atrial filling velocity (A), E-
wave deceleration time, and E/A-ratio were measured. Isovolumic relaxation time was 
measured from the start of the aortic valve closure signal to the start of mitral flow. The 
LVOT peak velocity was measured from the LVOT spectrum using low gain setting. The 
LVOT velocity time integral was measured by tracing the modal velocity throughout systole. 
From the pulmonary venous flow waveforms, peak systolic velocity, peak antegrade diastolic 
velocity.  
From the pulsed wave spectral TD recordings peak systolic mitral annular velocity 
(S′), peak early diastolic annular velocity (e′), and late diastolic velocity (a′ ) were measured 
at the peak of the Doppler spectrum with low gain setting (figure 5A). S′ were also measured 
at the peak of the curve obtained from colour TD (figure 5B). MAE was measured using 
anatomical M-mode echocardiography from the apical position (figure 5C) and from colour 
TD by integration of the TD velocity curves (figur 5C). Measurements of the septal, lateral, 
inferior and anterior walls were averaged for S′, e′, a′, MAE and LV length. E/e′ ratio was 
calculated by dividing E by the average e′(spectral TD) of the septal, lateral, inferior and 
anterior walls. In study three, S′ corrected for the ventricle length (S´/LV length) and the 
fractional shortening of the myocardium in long axis were calculated by dividing spectral TD 
S′ by spectral TD and M-mode MAE by the end-diastolic length of the left ventricle (99). All 
measurements reflected the average of three cardiac cycles during quiet respiration. 
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Figure 5: A: Spectral tissue Doppler (sTD) derived septal mitral annulus velocities. Peak 
systolic velocity S′(sTD), early diastolic velocity (e′(sTD)) and late diastolic velocity a′(sTD) 
measured at the maximum of the Doppler spectrum with low gain setting. B: Velocity curves 
from colour tissue Doppler (cTD). Peak systolic mitral annulus velocity S′(cTD) measured at 
the peaks. C: Measurements of systolic mitral annular excursion (MAE) by integrated velocity 
curves from colour tissue Doppler MAE(cTD) and by reconstructed M-mode MAE(Mm).  
4.3.3 2D and 3D wall motion analysis  
Two-dimensional wall motion score (WMS) was based on combined judgement of three 
apical views (4-chamber, 2-chamber and long-axis) and three parasternal views (mitral valve, 
papillary muscle, and apical short-axis planes), all recorded in B-mode. Three-dimensional 
WMS was analyzed in dynamic multi-slice view, obtained from the apex (figure 6). 
According to the American Society of Echocardiography recommendations, the LV was 
divided in a 16-segment model defined by various landmarks (1). Segmental WMS was 
graded as 1; normal, 2; hypokinetic, 3; akinetic, and 4; dyskinetic. The WMS was based on 
qualitative frame-by-frame judgement of the wall thickening of each segment. Segments with 
only passive movement or only post-systolic thickening were considered as akinetic. Wall 
motion score index (WMSI) was calculated by averaging the scored segments when ≥12 
segments were accepted for analysis.  
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Figure 6: Left: Three-dimensional wall motion analysis performed by dynamic multi-slice 
short axis views. Upper right: Bulls-eye presentation of wall motion scores (WMS) indicating 
inferoseptal myocardial infarction in a 16-segment model. Lower right: Two-chamber view 
with blue arrows indicating correction for out-of-plane motion caused by longitudinal 
shortening, which is more prominent at the basal level. 
4.3.4 Direct echocardiographic quantification of infarct size 
Longitudinal strain rate was obtained from colour TD recordings by calculating the velocity 
gradient. The cine loops were post-processed by in-house software (GC lab, ELVIZ). The 
regions of interest were tracked with TD along the ultrasound beam and grey-scale speckles 
perpendicular to the ultrasound beam, and the velocity gradient was sampled along curved M-
modes drawn along the LV walls. Strain rate data in the areas between the three standard 
planes were applied by cubic spline interpolation, assuming 60° rotation angle between the 
three apical planes and displayed as semi quantitative colour coded strain rate in a 
conventional bull’s eye view, as comprehensively described previously (21). The mid-systolic 
frame was selected for analysis, and on the sub segmental level, areas with mid-systolic strain 
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rate <-0.5 s-1 were automatically marked as normal, areas with mid-systolic strain rate -0.5 s-1 
to -0.25 s-1 were automatically marked as hypokinesia and areas with mid-systolic strain rate 
>-0.25 s-1 were automatically marked as akinesia (21, 100). Strain rate data in the apical ¼ of 
the apical segments were automatically discarded. Based on combined judgement of the 
colour coded strain rate data and wall motion analyses in the grey-scale recordings, the areas 
with marked hypokinesia and akinesia were manually corrected, but in the apical ¼ of the 
apical segments or in case of obvious artefacts in the strain rate analysis, the judgement of LV 
function was based on wall motion analyses in grey-scale recordings only. The areas of all the 
sub segments with hypokinesia and akinesia were divided by the total myocardial area and the 
total segmental area for estimation of global and segmental area fractions of hypokinesia and 
akinesia (Figure 7). Based on the previously reported relationship between infarct size and 
WMSI (91) and the relationship between the estimated infarct percentage obtained from peak 
TnT and the infarcted areas of the 13 patients without satisfactory LE-MRI. (101), the 
transmurality of the hypokinetic and akinetic areas were defined as 50% and 100%, 
respectively. Thus, the described area-based method gives a direct estimate of infarct size by 
echocardiography which can be directly compared to the infarct volume fraction given by LE-
MRI. 
 49 
 
Figure 7:  Composite figure displaying the direct quantification of infarct size by cSRs 
combined with WMA. Upper left: curved anatomic motion mode of cSRs during systole and 
early diastole. Lower left: bull’s eye view of cSRs during mid-systole. Arrows are indicating 
areas of suspected artefact and akinesia. Upper right: Three short axis views and three apical 
views of the left ventricle in B-mode recordings indicating WMA. Lower right: Based on 
combined judgement of cSRs and WMA, areas of hypokinesia and akinesia are marked and 
displayed as percentages of the total left ventricle area. Infarct size estimated assuming 50% 
infarct volume fraction in the hypokinetic areas and 100 % infarct volume fraction in the 
akinetic areas. Abbreviations: cSRs = tissue Doppler based colour coded systolic strain rate 
data; WMA = wall motion analysis. 
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4.3.5 2D Echocardiographic quantitative deformation analysis 
Two-dimensional longitudinal strain and strain rate were obtained by three different methods. 
For all the 4 studies, longitudinal strain was obtained by 2D speckle tracking in B-mode 
recordings (Automated Function Imaging; EchoPAC PC version BT 09-11, GE Vingmed, 
Horten, Norway). The regions of interest were manually adjusted to include the entire LV 
myocardium and simultaneously avoid the pericardium. Location of end-systole was manually 
corrected if necessary. The smoothing of the Automated Function Imaging EchoPAC 
software was not adjusted (i.e. default smoothing was used) in the first set of analyses. In 
study three and four a second set of longitudinal strain values were obtained by using exactly 
the same regions of interest, but with minimum smoothing in the adjustable post processing 
parameters of the Automated Function Imaging EchoPAC software. In study one the 2D 
speckle tracking method was also used to obtain segmental systolic and diastolic strain rate 
values. Peak systolic strain rate was measured as the maximal negative strain rate value 
during ejection time, early diastolic peak strain rate was measured as the maximal positive 
strain rate during the first part of diastole, and late diastolic peak strain rate was measured as 
the maximal positive strain rate during the last part of diastole.  
In study one and four 2D longitudinal strain and strain rate were also obtained from a 
semi automatic combination of TD and speckle tracking by customized software (GcMat; GE 
Vingmed Ultrasound, Horten, Norway) that runs on a MATLAB platform (MathWorks, Inc., 
Natick, MA, USA) (28). The kernels at the segmental borders were tracked with TD along the 
ultrasound beam and grey-scale speckles perpendicular to the ultrasound beam. Strain was 
calculated from the variation of segment length, and strain rate was calculated as the temporal 
derivative of strain, with correction to Eulerian strain rate. End-systolic strain was measured 
at aortic valve closure (25), and peak systolic strain rate was measured as the maximal 
negative strain rate value during ejection time. In study one this method was also used to 
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measure early diastolic peak strain rate as the maximal positive strain rate during the first part 
of diastole and late diastolic peak strain rate as the maximal positive strain rate during the last 
part of diastole. 
In study three longitudinal strain rate was calculated from colour tissue Doppler 
recordings, using the tissue Doppler velocity gradient along the ultrasound beam (Q-Analysis; 
EchoPAC PC version BT 09, GE Vingmed, Horten, Norway). For each segment a stationary 
region of interest with offset length 12 mm was manually positioned in the middle of the 
myocardium. The region of interest was adjusted up to 10 mm longitudinally and 5 mm 
laterally in order to avoid noise. Peak systolic strain rate was measured as the maximal 
negative value during ejection. 
For the three quantitative deformation methods, segments with poor tracking were 
excluded manually, and segmental values were obtained for each segment in the standard 
American Association of Echocardiography 16 segment model of the LV (1). Global averages 
of the segmental strain and strain rate values were calculated by averaging all the accepted 
segmental values, but in study three and four global averages were only calculated if at least 
12 segmental values were accepted for analyses. 
4.3.6 3D Echocardiographic quantitative deformation analysis 
Three-dimensional strain analysis was conducted using auto LV quantification (version BT11, 
GE Vingmed Ultrasound, Horten, Norway) (Figure 8). After manual alignment of the three 
apical views and the short axis view, points were placed in the mitral annulus plane and at the 
apex, in end-diastole and end-systole. End systole, which was defined as the frame with the 
smallest LV cavity, was automatically detected by the software, but manually corrected if 
necessary. End-diastolic and end-systolic volumes were measured by semi-automatic 
detection of the endocardial surface, with manual adjustment, and 3D LVEF was calculated. 
The epicardial border was automatically detected by the software and manually adjusted, in 
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order to delineate the region of interest for the analysis of end-systolic 3D longitudinal, 
circumferential, transmural and area strain. The strain values were obtained by a midwall 
tracking algorithm, based on frame-to-frame block matching in three dimensions. Area strain 
was calculated as the percentage variation in the midwall surface area. Finally, the tracking of 
each segment was manually controlled, and segments with sub-optimal tracking were 
manually rejected. Measurements of 3D global longitudinal strain, 3D global circumferential 
strain, 3D global transmural strain, and 3D global area strain were calculated by averaging the 
end-systolic segmental values when ≥12 segments had acceptable tracking (1). 
 
Figure 8: Analyses of global and segmental three-dimensional longitudinal, circumferential, 
radial (transmural), and 3D area strain in a patient with an apical anterior myocardial 
infarction. The regions of interest were delineated after semi-automatic detection of the 
endocardial surface and the epicardial borders in end-diastole and end-systole.  
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4.4 MRI acquisition and analysis 
4.4.1 MRI acquisition 
Examinations were performed on a 1.5 T Siemens Avanto (Siemens Medical, Erlangen, 
Germany) with a six-element body matrix coil. Late-enhancement images were obtained 10-
20 minutes after intravenous injection of 0.15 mmol/kg gadodiamide (Omniscan, GE 
Healthcare, Oslo, Norway) in multiple short-axis slices covering the LV. A balanced steady-
state free precision inversion recovery sequence was used, with ECG-triggered data 
acquisition in mid-diastole. Typical image parameters were: matrix 176x256, in-plane 
resolution 1.3x1.3 mm, slice thickness 8 mm, gap 2 mm, flip angelº, and inversion time 280-
350 ms. 
4.4.2 MRI analysis 
The LE-MRI analyses were performed by two operators (PH and BHA), using Segment v1.7 
(102). On each short-axis image, the total myocardial area as well as the area of infarcted 
myocardium was semi-automatically drawn. Areas with signal intensity more than two SDs 
above normal myocardium were considered infarcted. The infarct size was calculated as 
infarct volume in percentage of total myocardial volume. As short- and long-term mortality 
rates have been demonstrated to be increased in patients with infarct size >12% (103), 
patients were divided in small and large MI, using 12% as cut-off. Segments with infarct 
volume fraction >50% were classified as transmurally infarcted, while segments with infarct 
volume 1-50% were classified as sub-endocardially infarcted (65, 91). 
All echocardiographic and LE-MRI analyses were performed separately and blinded to 
other analyses and participant’s data.  
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4.5 Statistical analyses.  
Continuous variables are presented as mean ± SD. Categorical variables are presented as 
numbers (%). In study one the coefficient of repeatability was calculated according to the 
method of Bland and Altman as 2×SD of the differences in repeated measurements (66). The 
percentage error was derived as the absolute difference between the two sets of observations, 
divided by the mean of the observations (69, 71), and the mean error was defined as the 
average percentage error of each echocardiographic measurement. For comparison of the 
mean errors, one-way analysis of variance with post-hoc least significant difference (104) was 
used.  
In study two the relative changes between different contractile states were calculated 
as the measured difference between rest and the contractile state, divided by the measurement 
at rest. For multiple comparisons, one-way ANOVA with post-hoc Tukey correction were 
used. The area under the receiver operating characteristic curve (AUC) for detection of 
different contractile states was also used for comparison of the methods. We also calculated 
the intervals given by mean ± 2SD for indices at rest and during the different contractile 
states, and compared the percentage overlap relative to the mean at rest of these intervals. 
 In study three and four differences between small and large MIs and the healthy 
controls were analyzed by independent samples t-test. For the global indices, the relationship 
between the infarct size assessed by LE-MRI and each echocardiographic index was analyzed 
by bivariate correlation based on normal distribution among the final 58 patients and reported 
as Pearson's correlation coefficient (r). For the segmental indices, the relationship between 
each echocardiographic index and the segmental percentage infarct volume fraction assessed 
by LE-MRI was analyzed by bivariate rank correlations and reported as Spearman's 
correlation coefficient (r). Correlation coefficients were compared according to the method 
described by Meng et al (105). The area under the receiver-operating characteristic curves 
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(AUC) for the identification of small and large MIs is reported. AUC for the different 
methods was compared according to the method described by Hanley and McNeil (106). Cut-
off values giving the largest sum of sensitivity and specificity are reported. Statistical analyses 
were performed in SPSS version 17 (SPSS Inc, Chicago, Ill) 
5 Summary of results 
5.1 Feasibility (all studies) 
Estimation of biplane 2D and 3D LVEF, mitral annulus velocity and -motion indices, and 
flow Doppler indices were feasible in all recordings. On the segmental level the feasibility 
was 98% (1455 accepted segments out of 1488 segments) for 2D wall motion score, and 95% 
(1405 accepted segments out of 1488 segments) for 3D wall motion score, 99% (1469 
accepted segments out of 1488 segments) for direct quantification of infarct size by tissue 
Doppler strain rate and wall motion analyses (GC lab, ELVIZ), 83% (2932 accepted segments 
out of 3522 segments) for the 2D speckle tracking (Automated Function Imaging; EchoPAC), 
81% (1210 accepted segments  out of 1488 segments) for the combined 2D TD and speckle 
tracking method (GcMat), 85 % (1120 accepted segments out of 1314 segments) for the tissue 
Doppler velocity gradient method (Automated Function Imaging; EchoPAC), and 71% (1050 
accepted segments out of 1488 segments) for the 3D speckle tracking (Auto LVQ EchoPAC). 
5.2 The reproducibility study (study 1) 
In study one, the MAE by M-mode showed the best reproducibility with an inter-observer 
mean error of 4% and coefficient of repeatability of 1.6 mm. After correcting for multiple 
comparisons of the systolic indices in table 3, the inter-observer mean error of the MAE by 
M-mode was significantly lower (P<0.05) than the inter-observer mean error of the 
interventricular septal and posterior wall thickness, the fractional shortening of the 
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myocardium in short axis, the biplane end-diastolic and end-systolic volumes, the LVOT peak 
velocity, and the global peak systolic strain rate obtained by 2D speckle tracking. 
Table 3: Reproducibility of measurements of dimensions and global systolic function  
Table 3: Mean (standard deviation), coefficient of repeatability (COR) and mean error of 
systolic indices. IVSd (Mm) = end-diastolic interventricular septal thickness by M-mode,  
LVPWd (Mm) = left ventricular end-diastolic posterior wall thickness by M-mode, LVIDd 
(Mm) = left ventricular end-diastolic internal diameter by M-mode MAE(Mm) = systolic 
mitral annulus excursion by M-mode, MAE(cTD) = systolic mitral annulus excursion by 
colour tissue Doppler, S’(sTD) = peak systolic annulus velocity by pulsed wave spectral 
tissue Doppler, S’(cTD) = peak systolic annulus velocity by colour tissue Doppler, EDV = 
end-diastolic volume, ESV = end-systolic volume, EF = ejection fraction,  FS = fractional 
shortening of the myocardium in short axis, LVOT peak = left ventricular outflow tract peak 
velocity, SES (2D-ST) = end-systolic strain by the 2D-strain application, SRS (2D-ST) = peak 
systolic strain rate by the 2D-strain application, both measured by the 2D-strain application. 
Method Mean 
inter-observer 
COR  
inter-observer 
Mean Error 
inter-observer 
Mean Error 
inter-analyser 
Mean Error 
intra-analyser 
IVSd (Mm) 8.5 (1.1) mm 1.8 mm 12 % 10 % 10 % 
LVPWd (Mm) 7.7 (1.1) mm 2.4 mm 12 % 10 % 10 % 
LVIDd (Mm) 50 (5.3) mm 5.4 mm 5 % 5 % 3 % 
MAE (Mm)  17 (1.1) mm  1.6mm 4 % 3 %  3 % 
MAE (cTD)  15 (1.1) mm 2.2mm 7 % 4 %  2 %  
S′(sTD)  9.1 (2.0) cm/s 1.7 cm/s 8 % 3 %  2 % 
S′(cTD)  7.7 (1.4) cm/s 1.6 cm/s 7 % 3 % 2 %  
EDV biplane 108 (24) ml  14ml 12 % 8 % 8 % 
ESV biplane 44 (9) ml 9ml 9 %  10 % 9 % 
LVEF biplane 0.59 (0.05) 0.07 6 % 6 % 5 % 
FS 0.33 (0.06) 0.11 14 % 16 % 13 % 
LVOT peak 1.0 (0.1) m/s 0.2m/s 10 % 3 % 3 %  
Global SES (2D-St) 0.21 (0.02) 0.02 6 % 6 % 3% 
Global SRS (2D-St) -1.1 (0.01) s־¹ 0.2s־¹ 9% 5% 5% 
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After correcting for multiple comparisons of the diastolic indices in table 4 the inter-observer 
mean errors of the E, e′, a′ and the global early diastolic peak strain rate obtained by 2D 
speckle tracking were significantly (P<0.04) lower than the A, the E deceleration time, the 
E/A ratio, and the peak systolic and diastolic pulmonary venous flow velocity.  
 
Table 4: Reproducibility of global diastolic measurements  
Table 4: Mean (standard deviation), coefficient of repeatability (COR) and mean error of 
systolic indices, e′ = mean peak early diastolic velocity by pulsed wave spectral tissue 
Doppler, a′ = mean peak late diastolic velocity by pulsed wave tissue Doppler imaging, E = 
mitral flow peak early diastolic filling velocity, A = mitral flow peak late diastolic filling 
velocity, DT = E-wave deceleration time, IVRT = isovolumic relaxation time, PV S = 
pulmonary venous flow peak systolic velocity, PV D = pulmonary venous flow peak diastolic 
velocity diastolic, Global SRE = peak early diastolic strain rate, Global SRA = Peak late 
diastolic strain rate, both measured by the 2D-strain application. 
 
Another important finding of study one is that repeated analyses of the same recordings 
underestimate the clinically more relevant inter-observer reproducibility obtained by separate 
examinations by approximately 40% for most measurements of LV systolic function and 
approximately 50% for most measurements of LV diastolic function. Furthermore, the inter-
Method Mean 
inter-observer 
COR  
inter-
observer 
Mean Error 
Inter-observer 
Mean Error 
inter-analyser 
Mean Error 
intra-analyser 
e′ 14 (1.0) cm/s 3.4 cm/s 8% 3% 2% 
a′ 8.5 (2.5) cm/s 2.1 cm/s 9% 9% 2% 
E  74 (13) cm/s 12 cm/s 8% 5%  2%  
DT  175 (33) cm/s 10 cm/s  20%  17%  8%  
A 41 (12) cm/s 14 cm/s  18%  10%  4%  
E/A 2.0 (0.6) 0.35 22% 10% 5%  
IVRT  83 (9) ms 13 ms 17% 7% 3%  
E/e′ 5.4 (1.0) 1.3 11% 7% 3%  
PV S 55 (12) cm/s 12 cm/s 15% 4%  5%  
PV D 54 (7) cm/s 20 cm/s 16% 4%  4%  
PV S/D 1.0 (0.2) 0.38 12% 6% 6% 
Global SRE (2D-St) 1.6 (0.1) s־¹ 0.3s־¹ 7% 8% 7% 
Global SRA (2D-St) 0.8 (0.1) s־¹ 0.3s־¹ 13% 8% 12% 
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observer mean errors of e′ and a′ were reduced by 40% and 31% (P<0.022), respectively when 
4 instead of 2 walls were averaged. This corresponds to a reduction in the inter-observer mean 
error from 15% to 8% and the coefficient of repeatability from 4.9 cm/s to 3.4 cm/s for e′, and 
a reduction in the inter-observer mean error from 13% to 9% and the coefficient of 
repeatability from 2.7 cm/s to 2.2 cm/s for the a′. The mean error and the coefficient of 
repeatability of the S' were reduced from 11% to 8% and 2.3 cm/s to 1.7 cm/s when 4 instead 
of 2 walls were averaged. 
The inter-observer mean error and the coefficient of repeatability were 14% and 7.1% 
(percentage points) for segmental strain by 2D speckle tracking and 17% and 0.52 s-1 for peak 
systolic strain rate by 2D speckle tracking. When segmental strain and strain were averaged 
into global indices of LV performance, there were highly significant reductions of the mean 
errors by 60% for segmental strain and 44% for peak systolic strain rate. There were no 
significant differences in the reproducibility of 2D speckle tracking compared with the 
combined 2D tissue Doppler and speckle tracking method at the global level, but the inter-
observer mean error of segmental strain by 2D speckle tracking was significantly lower 
(P=0.03) than segmental strain by the combined 2D tissue Doppler and speckle tracking 
method. 
5.3 The contraction study (study 2) 
The systolic measurements were divided into peak systolic velocity indices (occurring during 
the rapid ejection phase) and end-systolic indices (reflecting the total work performed by the 
left ventricle during the ejection). S′ by spectral TD, S′ by colour TD, LVOT peak velocity 
and peak systolic strain rate by TD were defined as peak systolic velocity indices. Two-
dimensional and 3D LVEF, fractional shortening of the short axis, MAE by M-mode, MAE 
by colour TD, global longitudinal strain by 2D speckle tracking, and the LVOT velocity time 
integral, were defined as end-systolic velocity indices. 
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During stress the relative increase of the peak velocity indices ranged from 51% to 
62%, and these changes were significantly higher (all P<0.05) than the relative changes of all 
end-systolic indices which ranged from 21% to 31%. The range and the mean ± 2SD at rest 
and during stress overlapped for all indices except S′ by spectral TD, S′ by colour TD and 
peak systolic strain rate by TD (Figure 9 and Table 5). 
 
 
Figure 9: Individual changes of left ventricular ejection fraction (EF, global strain, and peak 
systolic velocity spectral tissue Doppler mitral annulus velocities (S`(sTD)) at rest, during 
low-dose dobutamine (upper panels) and after injection of metoprolol (lower panels). The 
mean (wide line), the mean ±2SD (narrow line) and the p-value of the change are displayed 
for each variable. The relative change during stress and after injection of metoprolol was 
highest for S`(sTD). 
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Table 5: Systolic echocardiographic indices at rest and during dobutamine. 
 Mean (SD) 
at  
rest 
Mean (SD) 
during 
stress 
Mean change 
(95% CI) 
Mean ±2SD 
overlap  rest vs 
dobutamine 
 (% overlap) 
AUC  
(95% CI) 
Peak systolic velocity indices 
S′(spectral TD)  9.4 (1.0) 
cm/s 
15.1 (1.8) 
cm/s 
62% 
(53 - 71)% 
-0.10 cm/s 
 (no overlap) 
1.00 
(1.00 – 1.00) 
S′(colour TD) 7.6 (0.9) 
cm/s 
11.5 (1.0) 
cm/s 
52% 
(43 - 62)% 
-0.06 cm/s  
 (no overlap) 
1.00 
(1.00 – 1.00) 
LVOT peak  1.0 (0.1) 
m/s 
1.7 (0.2) 
m/s 
60%  
(48 - 73)% 
0.11 m/s  
 (11%) 
0.99 
(0.99 – 1.00) 
Global SRs (TD)  -1.2 (0.1) 
s-1 
-1.8 (0.1) s-
1 
56% 
(50 - 61)% 
0.2 s-1  
 (no overlap) 
1.00 
(1.00 – 1.00) 
End-systolic indices 
Global strain (2D-
ST) 
-0.19 
(0.02) 
-0.23 (0.02) 21%  
(17 - 25)% 
3.4  
 (18%) 
0.95 
(0.86 – 1.00) 
LVOT vti 21 (4) cm 27 (4) cm 30%  
(20 - 40)% 
8.6 cm  
 (41%) 
0.89 
(0.79 – 1.00) 
MAE(M-mode)  15 (2) mm 20 (2) mm 30% 
(25 - 36)% 
2.8  
 (18%) 
0.96 
(0.91 – 1.00) 
MAE(colour TD) 15 (2) mm 18 (2) mm 23% 
(17 - 29)% 
3.4 mm  
 (23%) 
0.93 
(0.85 – 1.00) 
2D LVEF 0.57 (0.06) 0.70 (0.06) 25% 
(20 - 30)% 
0.11  
 (21%) 
0.95 
(0.89 – 1.00) 
3D LVEF 0.56 (0.04) 0.69 (0.04) 24%  
(21-27)% 
0.03  
(5%) 
1.00 
(1.00 – 1.00) 
FSS 0.32 (0.04) 0.42 (0.06) 31%  
(24 – 37)% 
0.10 
(32%) 
0.89 
(0.60 – 1.00) 
Table 5: AUC = area under the receiver operating characteristic curve for detection of 
increased contraction; CI = confidence interval; FSS = fractional shortening of the short 
axis; LVEF = left ventricular ejection fraction; LVOT = left ventricular outflow tract; MAE = 
mitral annulus excursion; S′ = peak systolic mitral annulus velocity; SD = standard 
deviation; SRs = peak systolic strain rate; ST = speckle tracking echocardiography; vti = 
velocity time integral; TD = tissue Doppler; 2D = two dimensional; 3D = three dimensional.  
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After injection of metoprolol, all indices decreased significantly (all P<0.05), except 
global strain, MAE by M-mode and 2D LVEF. The relative changes of the peak velocity 
indices ranged from -15 to -11 % and the relative changes of all end-systolic indices ranged 
from -5 to 1 %. There was a trend for all peak systolic indices to have higher AUC for 
detection of decreased contraction compared with the end-systolic indices, and this was 
significant for peak systolic strain rate by TD compared to all end-systolic indices and for 
S′(spectral TD) compared to global strain, MAE(M-mode) and 2D LVEF.  
The relative changes of the diastolic indices during stress and after metoprolol were 
less pronounced than the changes of the peak systolic indices. During stress the relative 
change of the diastolic indices ranged from 4% to 31%, and after injection of metoprolol the 
relative changes ranged from -9% to 14%. 
5.4 The infarction studies (study 3 and 4) 
5.4.1 Infarct Size by LE-MRI 
Evidence of MI was detected by LE-MRI in all patients. The mean (SD) infarct size was 11.4 
(8.1)% of the total LV myocardial volume. Thirty-three patients (57%) had calculated the 
infarct size <12% and 25 patients (43%) had infarct size >12%. Evidence of infarction by LE-
MRI was detected in 387 (42%) segments, with transmural extension (>50% late 
enhancement) in 74 (8%) segments (Figure 10).  
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Figure 10:  Histogram demonstrating the distribution of infarct size by LE-MRI. 
Abbreviations: LE-MRI = late enhancement magnetic resonance imaging. 
5.4.2 Echocardiography - Global indices 
There were significant differences between the patients with large MIs compared with those 
with small MIs or healthy controls for all the indices (Table 6). In patients with small MIs, the 
3D-LVEF was significantly lower (P<0.02) while direct echocardiographic quantification of 
infarct size and 2D- and 3D-WMSI were significantly higher (P<0.03) compared with the 
healthy controls. There were significant correlations between global infarct size assessed by 
LE-MRI and all the echocardiographic indices of LV global function with r = 0.51 for 3D-
LVEF, 0.55 for 2D-LVEF, 0.61 for FSL, 0.44 for S´/LV, 0.72 for 3D-WMSI, 0.74 for 2D-
WMSI, 0.81 for direct echocardiographic quantification of infarct size, 0.67 for global 
longitudinal strain by 2D speckle tracking with default smoothing, 0.66 for global 
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longitudinal strain by 2D speckle tracking with minimum smoothing, 0.56 for global 
longitudinal strain by 2D TD and speckle tracking, 0.44 for global longitudinal strain rate by 
2D TD and speckle tracking for 0.42 for global longitudinal strain by 3D speckle tracking, 
0.47 for global circumferential strain by 3D speckle tracking, 0.48 for global transmural strain 
by 3D speckle tracking, and 0.50 for global area strain by 3D speckle tracking. The 
correlation coefficient of direct echocardiographic quantification of infarct size was 
significantly higher (P<0.05) than all the other echocardiographic indices.  
The AUC for identification of large MIs ranged from 0.66 to 0.84 (Table 6). Direct 
echocardiographic quantification of infarct size demonstrated the highest AUC for separation 
of small vs. large MI, large MI vs. healthy controls and small MI vs. healthy controls, but the 
differences between methods were not statistical significant for most of the comparisons. A 
cut-off value of 7.0% by direct echocardiographic quantification of infarct size had a 
sensitivity of 72% and a specificity of 88% for separating small and large MI. Three-
dimensional-WMSI of 1.11 and 2D-WMSI of 1.14 had a sensitivity of 76% and 72% and a 
specificity of 72% and 74%, respectively, to separate small and large MI, while global 
longitudinal strain by 2D speckle tracking of 16.5% had a sensitivity of 68% and a specificity 
of 85% to separate small and large MIs. 
 The correlation coefficient of the peak cardiac troponin T with global infarct size 
assessed by LE-MRI was r = 0.66 (P<0.001). The AUC of the peak cardiac troponin T for 
separation of small vs. large MI was 0.79. Peak cardiac troponin T of 3.0 μg/L had a 
sensitivity of 92% and a specificity of 64% to separate small and large MIs.  
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Table 6 AUC for identification of large MI and transmurally infarcted segments of the 
different echocardiographic indices of global and segmental LV function 
 AUC (95% CI) of 
global indices for 
separation of large and 
small MIs 
AUC (95 % CI) of 
segmental indices for 
identification of 
transmurally infarcted 
segments  
Infarct size by the new method 0.84 * 
(0.73-0.94) 
0.89 § 
 (0.84-0.94) 
2D WMS 0.79 
(0.67-0.91) 
- 
3D-WMS 0.80 
(0.68-0.91) 
- 
2D longitudinal speckle tracking 
strain, default smoothing 
0.80 
(0.68-0.92) 
0.88 § 
 (0.83-0.93) 
2D longitudinal speckle tracking 
strain, minimum smoothing 
0.79 
(0.67-0.91) 
0.87 § 
 (0.82-0.92) 
2D longitudinal strain by TD and 
speckle tracking 
0.77 
 (0.65-0.90) 
0.80 § 
 (0.73-0.87) 
2D longitudinal strain rate by TD 
and speckle tracking 
0.70 
 (0.56-0.84) 
0.79 § 
 (0.73-0.86) 
2D-LVEF 0.78 
 (0.66-0.89) 
- 
3D-LVEF 
 
0.74 
(0.62-0.87) 
- 
FSL 0.78 
(0.65-0.91) 
- 
S´/LV length  0.72 
(0.57-0.85) 
- 
E/e′ 0.66 
(0.52-0.81) 
- 
3D longitudinal strain 0.72 
(0.56-0.88) 
0.73 
 (0.66-0.79) 
3D area strain  0.72 
 (0.57-0.87) 
0.85 § 
 (0.80-0.89) 
3D circumferential strain 0.69 
(0.53-0.84) 
0.87§ 
 (0.83-0.92) 
3D transmural strain 0.71 
(0.56-0.86) 
0.86 § 
 (0.82-0.90) 
Peak cardiac troponin T 0.79 
(0.68-0.90) 
- 
Table 6:  Large MI: total infarct volume fraction >12% by LE-MRI. Small MI: total infarct 
volume fraction <12% by LE-MRI. Transmurally infarcted segments: segmental infarct 
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volume fraction >50%. * = AUC significantly (P≤0.05) higher than 2D longitudinal strain 
rate by TD and speckle tracking, S´/LV length, E/e′, 3D longitudinal strain, 3D area strain, 
3D circumferential strain and  3D transmural strain  § = AUC significantly (P≤0.01) higher 
than 3D longitudinal strain; AUC = area under the receiver operating characteristic curve; 
CI = confidence interval; E = peak early diastolic velocity; e` = mean peak early diastolic 
mitral annular velocity; FSL = fractional shortening of the longaxis; LV = left ventricular; 
LE-MRI = late enhancement magnetic resonance imaging; LVEF = left ventricular ejection 
fraction; MI = myocardial infarction; new method = combined judgement of colour coded 
strain rate data and wall motion analysis; S`= peak systolic mitral annulus velocity; WMS = 
wall motion score; 2D = two-dimensional; 3D = three-dimensional. 
 
Of the patients with LE-MRI infarct size <6%, hypokinetic or akinetic areas were only 
identified in 6 patients (32%) by the direct echocardiographic quantification of infarct size 
and in 5 patients (26%) by 2D and 3D WMS. The direct echocardiographic quantification of 
infarct size underestimated the infarct size by 4.2 % (95 % limits of agreement -14.3% to 
5.9%) compared to LE-MR. 
5.4.3 Echocardiography - Segmental indices 
The mean segmental values of the non-infarcted, sub-endocardial infarcted and transmurally 
infarcted segments were significantly different for all the echocardiographic methods. There 
were significant correlations between segmental infarct volume fraction assessed by LE-MRI 
and all the segmental echocardiographic indices with r = 0.53 for 3D-WMS, 0.53 for 2D-
WMS, 0.59 for direct echocardiographic quantification of infarct size, 0.48 for longitudinal 
strain by 2D speckle tracking with default smoothing, 0.46 for longitudinal strain by 2D 
speckle tracking with minimum smoothing, 0.39 for longitudinal strain by 2D TD and speckle 
tracking, 0.31 for longitudinal strain rate by 2D TD and speckle tracking, 0.25 for longitudinal 
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strain by 3D speckle tracking, 0.40 for circumferential strain by 3D speckle tracking, 0.40 for 
transmural strain by 3D speckle tracking, 0.40 for area strain by 3D speckle tracking. 
The correlations of 3D-WMS, 2D-WMS, direct echocardiographic quantification of 
infarct size, and longitudinal strain by 2D speckle tracking with default and minimum 
smoothing with segmental infarct volume fraction were significantly higher compared to the 
other echocardiographic indices (all P<0.05). In addition, the correlation coefficients for 
longitudinal strain by 2D TD and speckle tracking and circumferential, transmural and area 
strain by 3D speckle tracking were significantly higher than for longitudinal strain by 3D 
speckle tracking (all P<0.03). The correlation coefficient between 3D-WMS and 2D-WMS 
was 0.74. The correlation coefficient between segmental longitudinal strain by 2D speckle 
tracking and longitudinal strain by 2D TD and speckle tracking were 0.74. The correlations 
between the four different measurements of segmental 3D strain were generally strong (all 
r>0.79), except the correlation between longitudinal and circumferential strain by 3D speckle 
tracking (r = 0.43).  
All the segmental echocardiographic indices showed generally good ability to identify 
transmurally infarcted segments with more than 50% contrast enhancement by LE-MRI 
(Table 6). However, the AUC for longitudinal strain rate by 2D TD and speckle tracking and 
longitudinal strain by 3D speckle tracking was significant lower (all P<0.01) than the other 
echocardiographic indices. Otherwise, the differences in AUC of the echocardiographic 
indices were not statistically significant. Three-dimensional-WMS and 2D-WMS >1 had a 
sensitivity of 73% and 77% and a specificity of 95% and 94%, respectively, for identification 
of transmurally infarcted segments, while longitudinal strain by 2D speckle tracking with 
default smoothing of >-14.4% had a sensitivity of 80% and a specificity of 85% for 
identification of transmurally infarcted segments.  
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5.4.4 Data reproducibility 
Reproducibility of study three and four was assessed by one of the co-authors reanalyses of 20 
randomly selected recordings. For the global echocardiographic indices the coefficient of 
repeatability was 0.21 for 3D WMSI, 0.19 for 2D WMSI, 9.7% for direct echocardiographic 
quantification of infarct size, 2.2% for global longitudinal strain by 2D speckle tracking, 2.9% 
for global longitudinal strain by 2D TD and speckle tracking, 0.20 s-1 for global longitudinal 
strain rate by 2D TD and speckle tracking, 4.1% for global longitudinal strain by 3D speckle 
tracking, 5.7% for global circumferential strain by 3D speckle tracking, 12.2% for global 
transmural strain by 3D speckle tracking, and 6.1% for global area strain by 3D speckle 
tracking.  
For the segmental echocardiographic indices the weighted kappa coefficient was 0.72 
for 3D WMS and 0.67 for 2D WMS. The coefficient of repeatability was 33% for direct 
echocardiographic quantification of infarct size, 6.6% for longitudinal strain by 2D speckle 
tracking, 5.7% for global longitudinal strain by 2D TD and speckle tracking, 0.52 s-1 for  
longitudinal strain rate by 2D TD and speckle tracking, 8.3% for longitudinal strain by 3D 
speckle tracking, 10.3% for circumferential strain by 3D speckle tracking, 25.2% for 
transmural strain by 3D speckle tracking, and 11.9% for area strain by 3D speckle tracking. 
6 Discussion 
6.1 Main findings 
As hypothesized in study one, repeated analyses of the same recordings severely 
underestimated the clinically more relevant inter-observer reproducibility obtained by 
separate examinations. MAE by M-mode seemed to show the best reproducibility.  
In study two peak systolic velocity indices (mitral annulus tissue velocities, ejection 
velocities and strain rate) exhibited greater variation than end-systolic indices during inotropic 
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alterations, which supports the hypothesis that the peak systolic velocity indices better reflect 
changes in contraction compared to the end systolic indices. 
In study three we were able to quantify the percentage infarct size by 
echocardiography with high accuracy. As hypothesized in study three, strain rate imaging 
adds incremental diagnostic value to wall motion score in B-mode, and this new method 
combining strain rate imaging and wall motion analysis showed better correlation to LE-MRI 
compared with other echocardiographic indices of global LV function. 
In study four we hypothesized that 3D echocardiography would provide added 
diagnostic value in patients with recent myocardial infarctions. However, we could not prove 
better overall accuracy of 3D echocardiography compared with 2D echocardiography. WMS 
by dynamic multi-slice short-axis obtained from only one 3D recording gave a quick and 
reliable view of the LV regional function with added diagnostic value in several patients, 
particularly those with better apical acoustic window, but added diagnostic value of the tested 
implementation of 3D strain could not be proven. 
6.2 Study population and study design 
None were excluded due to inadequate echocardiographic images in the four papers, meaning 
that the results are not idealised. 
6.2.1 The reproducibility study (study 1) 
The study population of study one was selected among people who reported to be free from 
cardiovascular disease. The participants were fairly young, and had fair image quality. 
Reproducibility might be expected to be lower in a general patient population. In all 20 
separate echocardiographic examinations (10 participants) were recorded. Thus, clinical 
important differences in reproducibility could be tested, but this study population had limited 
power to detect small differences in the reproducibility of different measurements. Those 
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differences however, can be assumed to be of less clinical importance. It is likely that the 
population of study one is representative for the population of study two. Thus, we assume 
that the reproducibility analyses of study one is representative for the reproducibility of the 
echocardiographic measurements of study two. The age, cardiac function and 
echocardiographic image quality of participants were significantly different in study one 
compared with study three and four. Thus, the reproducibility analyses of study one can not 
directly be generalized to study three and four.  
 The inter-observer reproducibility analyses of study one were based on 
different recordings obtained from different physician echocardiographers. Compared to 
repeated analyses of single recordings, test-retest analyses of separate recordings are more 
clinically relevant and better reflect the repeatability and imaging related variability of 
echocardiographic parameters in everyday clinical practice. Standard parameters for 
assessment of systolic function are strongly influenced by biological variation, and we sought 
to minimize these by repeating the study over a short time frame, so that the main source of 
variation was related to imaging per se.  
6.2.2 The contraction study (study 2) 
The study population of study two was selected among young people who reported to be free 
from cardiovascular disease. This relatively homogeneous population was chosen in order to 
induce uniform alterations in contraction in order to compare the ability of different 
echocardiographic methods in detecting contractility changes. Any unphysiological response 
to dobutamine or metoprolol, for instance due to ischemia, would have biased the results. We 
believe that the deliberate careful selection of a homogenous population of young and healthy 
subjects was favourable and may have contributed to clear and robust differences between the 
methods. However, detection of contraction changes in healthy subjects might be detection 
different from changes in cardiac function of patients with cardiac diseases. 
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The aim of the protocol was to obtain 20 paired rest-dobutamine recordings and 20 
paired rest-metoprolol recordings, which were achieved without discontinuation or exclusion 
of any examination. However, in case of residual effects of dobutamine in the metoprolol 
study, we did preliminary analyses of the data of the seven first subjects who received both 
dobutamine and metoprolol. As there was a trend towards a smaller decrease in heart rate 
after injection of metoprolol of these subjects, we decided not to give both dobutamine and 
metoprolol to all the subjects. Thus only 7 of 33 underwent imaging in the basal state and 
after both dobutamine infusion and metoprolol infusion, whereas 13 patients underwent 
imaging in the basal state and during low-dose dobutamine stress, and another 13 patients 
underwent imaging in the basal state and after metoprolol infusion. The final analyses of the 
echocardiographic indices after metoprolol infusion did not indicate that the seven subjects 
who received dobutamine before metoprolol responded significantly differently from the 13 
subjects who only received metoprolol. 
 The main effect of dobutamine at low dose is increased inotropy without a profound 
effect on heart rate (107), and it is thus well suited for studying changes in contraction and 
contractility. In line with previous studies, low-dose dobutamine increased the heart rate by 13 
% (108, 109), and metoprolol reduced the heart rate by 12 %. No invasive reference method 
was used, but dobutamine and metoprolol have well-documented positive and negative 
inotropic effects, and has previously been used to define inotropic states in several studies 
(47, 107, 109, 110), and we therefore found it ethically unacceptable to let healthy subjects 
undergo an invasive procedure for this purpose. Low-dose dobutamine has previously induced 
>50 % increase in the maximal first derivative of left ventricular pressure (LV dP/dtmax) 
obtained by cardiac catheterization in different populations, (111-113) which is in the same 
range as the measured increase of peak systolic velocity indices during low-dose dobutamine 
in this study. Thus the “gold standard” is that the data belongs to one of three contractile 
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states, betablocker, baseline or dobutamine, and the aim of the study was to test the ability of 
different measurements to detect the contraction changes given á priori.  
6.2.3 The infarction studies (study 3 and 4) 
The study population consisted of patients with a mean age of 55 years, and approximately 
75% were men. The predominance of males is in accordance with multicenter trials of 
patients with myocardial infarction in which about 25–30% of women were recruited (114, 
115). Other studies have shown that women with first time myocardial infarction were older 
and had a higher prevalence of hypertension and kidney failure (116, 117) compared with 
men. There was much focus in medical literature and public media on the risks of 
development of nephrogenic systemic fibrosis induced by gadolinium-based contrast at the 
time of inclusion. Therefore we were particularly careful in the judgement of the renal 
function. Thus, it is likely that more women than men were excluded due to age >75 years 
and kidney failure. Furthermore 5 of the 11 drop outs were women. There was a balanced 
representation of all the three main coronary arteries identified as the culprit lesion. Although 
approximately 80% of the MI’s was STEMI and only patients with peak troponin T levels 
below 0.5 μg/L were included, approximately 30% had infarct size below 6%. A subgroup of 
NSTEMI patients has substantial myocardial necrosis, but the majority of NSTEMI patients 
have small myocardial infarctions typically with peak troponin T levels below  0.5 μg/L 
troponin T (90, 118). There was a predominance of males, few patients with diabetes mellitus 
and hypertension in the study population, no unstable patients, and no patients with severe 
heart failure. Otherwise, the patients in study three and four in whom the majority were 
STEMI patients treated with acute PCI, may reflect the population of moderate to large first 
time MI in most coronary care units.  
The sex and age matched healthy controls of study three and four were selected from 
the participants randomized to echocardiography in the third wave of the HUNT Study. Both 
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the cardiac risk factors and the echocardiographic indices of LV function of the participants of 
the HUNT3 Echocardiography sub-study followed a normal distribution (119). Nevertheless, 
all population studies are sensitive to a selection bias. For all participants simultaneous 
symptoms or knowledge of cardiac risk factors may increase the attendance rate in a cardiac 
ultrasound study as health examination may be more attractive to subjects with any symptoms 
or higher level of risk (120). However, the Echocardiography in HUNT3 was only one of 
many sub-studies. Both the randomization of participants to the different sub-studies, and the 
exclusion of participants with known cardiovascular disease, diabetes and hypertension may, 
at least partly, reduce this bias. The mean body mass index of the healthy controls of study 
three and four was 26.1 kg/m2, which indicate that more than 50 percent of the healthy 
controls were classified as overweighed or obese (121, 122). However, with the today’s 
epidemic of obesity in mind this may reflect normality, as it reflects the worldwide change in 
body mass index (123). Surprisingly, the creatinine level of the healthy controls was 
significantly lower than the patients with recent MI. This might be explained by the careful 
judgement of the renal function prior to inclusion of the MI patients. 
6.3 Echocardiographic acquisition and analysis 
6.3.1 Echocardiographic image acquisition. 
In all four studies we used scanners, transducers and software from GE Vingmed, (Horten, 
Norway). As there are differences between, manufacturers, the results can not be 
unconditionally generalized to other manufacturers. We used clinical applicable wide sector 
acquisition as we sought to investigate the clinical use of grey scale and tissue Doppler 
echocardiography. The frame rate is inversely related to line density (number of lines in the 
scanner sector). As we used the default frame rate setting, the frame rate was only adjusted by 
adapting the width of the sector to encompass the LV walls. However, the recordings of the 
fourteen patients in study three and four who were examined with a newer scanner, had 
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significant higher frame rate compared with the other patients and the healthy controls. All the 
recordings of the four studies were obtained by two experienced echocardiographers (Anders 
Thorstensen and Håvard Dalen).  
6.3.2 Analysis of B-mode and Doppler echocardiography. 
Study one showed that a conventional method like MAE by M-mode was at least as good as 
global longitudinal strain by 2D speckle tracking or TD in terms of reproducibility. MAE by 
M-mode showed also good correlation with LE-MRI and good ability to separate small and 
large MIs. The correlation of MAE by M-mode with LE-MRI was higher than for LVEF and 
lower than for global longitudinal strain by 2D speckle tracking, but these differences were 
not statistically significant. Two dimensional and 3D LVEF showed fair correlation with LE-
MRI and good ability to separate small and large MIs. Despite, the superior accuracy and 
reproducibility of 3D-LVEF compared to 2D-LVEF demonstrated in multiple studies (51, 52), 
added diagnostic value of 3D-LVEF could not been shown in this thesis. LVEF by either 2D 
or 3D echocardiography did not show the best reproducibility, showed limited ability to detect 
contraction changes and only moderate correlations with LE-MRI. Thus, the overall results of 
the thesis indicate that LVEF may not be the optimal measurement of LV function. 
 S′ is an attractive method in everyday clinical practice as it is easy and fast to obtain 
with low demand of post-processing. In study two S′ by spectral TD and S′ by colour TD 
averaged over four walls showed excellent ability to detect contraction changes induced by 
dobutamine and beta-blocker. S′ measures the peak velocity of the mitral annulus motion, 
occurring in the first part of systole, and in line with our hypothesis S′ better reflected the 
contraction changes compared with end-systolic indices like MAE by M-mode, global strain 
and LVEF. However, S′ by spectral TD showed weaker correlation with LE-MRI compared 
with MAE by M-mode, 2D and 3D WMS, and direct echocardiographic quantification of 
infarct size. Other studies of patients with MI have also shown that S′ had weaker correlation 
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with the reference methods compared to regional deformation indices (124-126), while 
experimental studies have shown that S′ better reflects myocardial contractility compared with 
end-systolic indices (47, 109, 110). Thus, the apparently contradictive results of study 2-4 
might be explained by preserved LV global contractility of the patients with small or medium 
large MI. Furthermore, S′ is a measurement of LV global function due to tethering effects 
between LV walls (41), and global average of regional indices may be the best measurements 
in conditions with regional dysfunction. 
E/e′ has been shown to be a useful prognostic index and is established as an index of 
LV filling pressure (127), but E/e′ showed weaker correlation than most other measured 
indices of LV performance. E/e′ is a combined measurement of two diastolic indices and 
diastolic indices might be inferior to systolic measurement in estimation of infarct size. In 
addition, E/e′ and other diastolic indices are very dynamic parameters and particularly 
sensitive to changes in loading conditions, and as shown in study one, E/e′ and other diastolic 
indices, were inferior to systolic indices in terms of reproducibility.   
In order to avoid variability due to ventricular size, MAE and S′ were divided by the 
end-diastolic length of the left ventricle (128). However, correcting for the end-diastolic 
length led only to a trend towards increase in the diagnostic accuracy which was not 
statistically significant (data not shown). However, it may be noted that the variability in LV 
size was small, as 80% of the subjects were men. The fractional shortening of the 
myocardium in long axis is a measurement of LV global longitudinal strain, and as expected, 
the fractional shortening of the myocardium in long axis and global longitudinal strain by 2D 
speckle tracking showed high mutual correlation and similar diagnostic accuracy.  
6.3.3 2D and 3D wall motion score  
Two-dimensional and 3D-WMS showed strong correlation with LE-MRI and excellent ability 
to separate small and large MIs, and good ability to identify transmurally infarcted segments. 
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WMS showed better correlation with LE-MRI than the other measured indices of LV global 
performance, except longitudinal strain by 2D speckle tracking and direct quantification of 
infarct size. Similar diagnostic accuracy of WMS and 2D speckle tracking echocardiography 
in patients with MI has also been shown by others (90, 129).  
The results of study three and four show that 3D-WMS by dynamic multi-slice 
obtained from only one 3D recording provides a quick and reliable view of the LV function. 
Wall motion score in 2D recordings can be difficult due to in- and out-of-plane motion, 
tethering and the limited coverage of the LV. Also, due to the longitudinal motion of even 
akinetic segments, the wall thickening is more difficult to discern visually. When looking at 
dynamic short axis slices, only wall thickening is seen. In some cases with better apical 
acoustic window, 3D-WMS showed added diagnostic value, but as 2D echocardiography 
performed better in subjects with better parasternal acoustic window, the overall accuracy of 
3D-WMS and 2D echocardiography did not differ significantly. Comparing the entire LV 
circumference in dynamic short-axis slices from a 3D recording makes it easier to separate 
areas with reduced function, and this may compensate for the lower temporal resolution and 
larger voxel size in 3D. In daily routine, this would be a clear advantage in patients with 
limited parasternal acoustic window, where short-axis images are hard to get.  
6.3.4 Direct echocardiographic quantification of infarct size 
In study three, we present a new method for direct echocardiographic quantification of infarct 
size based on interpolation of semi quantitative colour coded strain rate in bull’s eye views. 
On the sub segmental level, areas were automatically marked as normal, hypokinetic, or 
akinetic, and divided by the total myocardial area and the total segmental area for estimation 
of global and segmental area fractions. However, TD based strain rate is sensitive to signal 
noise and acoustic artefacts, and the accuracy of the automatic quantification of infarct size 
based on TD strain rate alone was unsatisfactory. Manual correction of the strain rate data by 
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wall motion analysis was necessary to achieve high accuracy. Thus, the method is not a 
replacement of wall motion score, which still can be said to be part of the method. Direct 
echocardiographic quantification infarct size by colour coded strain rate and wall motion 
analysis yields high diagnostic accuracy and better correlation to LE-MRI compared with the 
other measured indices of LV global performance. The strain rate data yielded additive 
diagnostic information to wall motion analysis. Similar results have been reported previously 
(22, 24) and underscore the versatility of echocardiography and the advantage of performing 
an integrated judgment, using more than one echocardiographic method. However, in a recent 
publication the combined use of WMS and longitudinal strain by 2D speckle tracking did not 
increase the diagnostic accuracy compared with the accuracy of the two methods used alone 
(90). This might indicate that strain rate data to a greater extent than speckle tracking 
echocardiography is helpful for counteracting misinterpretations due to passive motion caused 
by tethering in wall motion analyses. Although strain rate data is sensitive to signal noise and 
acoustic artefacts and the segmental 95% confidence interval of trace analysis is rather wide 
(28), identification of MI and artefacts are often easy when TD based strain rate is displayed 
as semi-quantitative colour information in curved M-mode. Direct quantification of 
percentage infarct size by echocardiography may be particularly attractive for patients and 
health workers who are not familiar with the terminology of advanced echocardiography. All 
the other methods, except WMSI which measure the extent of infarction semi-quantitatively, 
are measurements of global LV function, where the degree of reduced function only may 
serve as an indirect estimate of infarct size, and the units and magnitude these methods may 
be difficult to relate to infarct size and difficult to interpret for many patients and health 
workers. 
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6.3.5 2D echocardiographic quantitative deformation analysis 
In study one, the test-retest variability reproducibility was good for global longitudinal strain 
by 2D speckle tracking, but the test-retest variability was high on the segmental level, 
suggesting use of clinical watchful approach when performing regional analyses. In study 
two, strain by 2D speckle tracking was clearly inferior to peak systolic velocity measurements 
in detecting contraction changes. Strain by 2D speckle tracking also showed weaker 
correlation with LV pressure development compared with S′ and strain rate in animal models 
(47, 109, 110). Thus, longitudinal strain by 2D speckle is probably not the optimal non-
invasive index for measuring myocardial contractility. In study three and four, longitudinal 
strain by 2D speckle tracking had high correlation with LE-MRI, good ability to identify large 
MIs and transmurally infarcted segments. Although, direct echocardiographic quantification 
showed better correlation with LE-MRI the accuracy of 2D speckle tracking 
echocardiography was comparable. The correlation of 2D speckle tracking with LE-MRI was 
significantly better than for longitudinal strain rate and strain rate by 2D TD and speckle 
tracking, both on the global and the segmental level. Strain analyses by the speckle tracking 
method is less angle dependent and may be less sensitive to signal noise and acoustic artefacts 
compared with TD analyses, although this to at least some degree is due to a liberal amount of 
spatial smoothing. However, in line with other studies (90, 91, 129) the accuracy of 2D 
speckle tracking echocardiography was no better than wall motion score. Thus, there is still 
potential for further technological development of quantitative deformation imaging. The cut-
off values longitudinal strain by 2D speckle tracking (-16.5%) for separation of small and 
large MI presented are in line with others (91, 93). Sjølie et al presented a cut-off value of -
15.0% for identification of infarct size >20% in a study of 39 STEMI patients in whom 
echocardiography was performed approximately 10 days after hospital admittance (93). As 
expected due to acute stunning effects, the cut-off values were different in a study where 
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echocardiography was performed immediately before revascularization (90). There was no 
significant difference in the correlation with LE-MRI or the accuracy of detecting large MIs 
or transmural infarcted segments, when the regions of interest was reanalysed using minimum 
smoothing by the 2D speckle tracking method. However, the average end systolic strain 
values obtained by minimum smoothing were significant lower (P < 0.001) for small MIs, 
large MIs and healthy controls (in average 0.4% (percentage points) higher absolute strain 
values for the whole study population).  
 In study one, the test-retest reproducibility of global longitudinal strain and strain rate 
obtained from the combination of speckle tracking and TD was comparable to the 
commercially available speckle tracking strain method, but the test-retest variability was 
unsatisfactory high on the segmental level. TD imaging has a high component of random 
noise, which may lead to measurement at the top of noise spikes, which may incorporate a 
component of noise in the estimate of peak values. In study three and four, strain and strain 
rate obtained from the combination of speckle tracking and TD showed significantly lower 
correlation with infarct size by LE-MRI compared with longitudinal strain by speckle tracking 
both at the global and segmental level. However, TD based methods could provide additional 
information that is not present in grey-scale recordings. For instance, is the timing of events in 
the cardiac cycle more reliable in TD analyses, due to the much better temporal resolution.  
 In study two, we wanted to use only commercially available methods, and therefore 
we calculated the strain rate values from the tissue Doppler velocity gradient method. Peak 
systolic strain rate by TD showed excellent ability to detect contraction changes. However, in 
order to achieve reasonable strain rate values by the tissue Doppler velocity gradient method, 
the regions of interests had to be adjusted, and only minor adjustment of the regions of 
interest had huge impact on the strain rate values. In addition, it was easy for the analysers to 
recognise that the myocardium was influenced by Dobutamine. Thus, this method is probably 
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more subjective and operator depended than the other methods. In our opinion trace analyses 
by tissue Doppler velocity gradient method are accurate and useful in clinical practice in the 
timing of cardiac events (130), but when performing regional analyses we recommend that the 
trace analyses should be supplemented by semi-quantitative colour coded curved M-mode or 
bull’s eye views in which identification of MI and artefacts are more easy.   
6.3.6 3D echocardiographic quantitative deformation analysis 
The four different measurements of 3D strain in study 4 were able to identify most patients 
with infarct size >12%, but considering the lower feasibility and more moderate correlations 
to LE-MRI of 3D strain compared with wall motion analysis and 2D speckle tracking 
echocardiography, added diagnostic value of the tested implementation of 3D strain could not 
be proven. ST-echocardiography and other quantitative deformation analyses are sensitive to 
low frame rate, signal noise, and artefacts. Despite acquiring the 3D recordings over four to 
six consecutive heart beats, both the temporal and spatial resolutions were considerably lower 
in 3D than in 2D. This is probably the cause of the low correlation between longitudinal 3D 
strain and LE-MRI; longitudinal motion is higher at the base, where resolution is lower. 
Furthermore, stitching artefacts in 3D recordings are more likely to cause misinterpretation in 
speckle tracking than in visual wall motion analysis. A recent publication reported accurate 
and reproducible 3D strain measurements in a study which mainly included healthy subjects 
and patients with ischemic and non-ischemic cardiomyopathy (131), but this study population 
was selected on the basis of image quality and their results were not validated by MRI. 
6.3.7 Global versus segmental analyses 
Segmental analyses are challenging. In Study 1 the test-retest variability, assessed by mean 
error (absolute difference divided by the mean of two observations) of global strain analyses 
by two different methods (AFI and GcMat) was 4-6%, compared to 14-18% in segmental 
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analyses. Previously it has been shown that the normal ranges are much wider for segmental 
indices compared with global indices. These findings indicate the main limitations of 
segmental analyses (28), and the need for special awareness of methodological and technical 
limitations of the method used. The results of study one and two showed that global indices of 
LV performance by conventional methods was comparable to methods based on global 
average of regional deformation indices. In addition, conventional methods like MAE by M-
mode and S′ appear superior to deformation imaging with respect to feasibility and time 
efficiency, as deformation analysis for instance by speckle tracking echocardiography require 
experienced critical judgement of the tracking of each segment. However, in study three and 
four global average of regional deformation indices generally showed the strongest 
correlations with LE-MRI than conventional methods. Thus, regional indices seems to be 
preferable in conditions with regional dysfunction 
6.3.8 Methodological differences - strengths and weaknesses  
The different methods used in these studies illustrate to some degree the armamentarium of 
methods used in echocardiographic laboratories. Although, LVEF is the most commonly used 
measurement of LV function, the overall results of the thesis indicate that LVEF may not be 
the optimal measurement. LVEF is a key functional and prognostic marker of LV function. 
Low LVEF correlates well to mortality, but the method is inferior to the more modern 
methods with respect to quantification of LV function (49, 132). LVEF overestimates the 
myocardial function in small hypertrophic hearts, has limited reproducibility and is a poor 
indicator of the contractile properties of the myocardium (33). In line with previous studies 
peak cardiac Troponin T showed better correlation with infarct size by LE-MRI than LVEF 
(96). 
The annular tissue velocity and motion measurements have shown ability to 
differentiate between sick and healthy myocardium, and as well predict mortality (133-136). 
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The pulsed wave spectral TD method is performed online, while the colour TD requires 
offline post-processing. The pulsed wave spectral TD method is recommended by the 
European and the American Associations of Echocardiography due to more validation studies 
than the colour TD method. (127). However, in the Copenhagen Heart Study colour TD 
systolic mitral annular velocity predicted mortality (133). As shown in this thesis the two 
tissue Doppler methods for assessing myocardial velocities differ with respect to methodology 
and the absolute values obtained, with lower values by the colour TD method. However, they 
seem equal with respect to reproducibility and identification of contraction changes. 
Controversies about correct gain settings and localization of the peak in the Doppler spectrum 
points is an important limitation of the spectral TD method (Figure 11), but the colour TD 
method requires off-line post processing and is more prone to acoustic artefacts. 
 
Figure 11. Pulsed wave spectral TD assessed velocities from the base of the inferior LV wall 
with low gain settings in the left recording and the high gain settings in the same recording at 
right. Green line refers to peak systolic velocity measured at the outer edge of the Doppler 
spectrum at low gain, and with high gain it is obvious that similar method measure higher 
velocity. Red line refers to peak early diastolic velocity at low gain, and similarly it looks like 
the velocities are higher when gain is increased. 
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WMSI is an established parameter of LV systolic function, validated as a prognostic indicator 
after MI. However, it is semi quantitative, experience dependent, and based on subjective 
interpretation of the wall thickening. Despite lower spatial and temporal resolution of 3D 
echocardiography, 3D WMS showed similar diagnostic accuracy as 2WMS. Analyses in short 
axis are often preferable when performing wall motion analysis as passive longitudinal 
motion caused by tethering of adjacent myocardium may cause misinterpretations in long axis 
views. Also, the longitudinal motion makes discernment of the wall thickening component 
visually challenging. Comparing the entire LV circumference in dynamic short-axis slices 
from a 3D recording makes it easier to separate areas with reduced function, and this may 
compensate for the lower temporal resolution and larger voxel size in 3D. In daily routine, 
this would be a clear advantage of 3D echocardiography in patients with limited parasternal 
acoustic window, where short-axis images are hard to get.  
A possible explanation to the difference between 2D WMSI and direct 
echocardiographic quantification of infarct size is that the areas of hypokinesia and akinesia 
are classified on a sub-segment level and reported as continuous data by the new method. This 
may increase the diagnostic accuracy compared to WMSI, which dichotomize each segment 
into ordinal data. In addition, the new method corrects for the area distortion in the bull’s eye 
view, while WMSI has no correction for unequal segment size, apart from the reduced 
number of segments in the apex. Echocardiographic measurements like LVEF, MAE S´, E/e, 
and global strain and strain rate, may yield measurements that are in the border zone between 
normal and decreased LV function, while direct echocardiographic quantification of infarct 
size and WMSI dichotomizes each segment or sub segment as either healthy or diseased.  
Thus, infarct size above 0 or WMSI above 1.0 are more conclusive indications of visible MI.  
When comparing the quantitative deformation indices, the different methods differ 
with respect to the technological basis and how user-friendly the interface is. TD based 
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deformation indices have a high component of random noise, which may lead to measurement 
at the top of noise spikes, and this may incorporate component of noise in the estimate of peak 
values. The high SDs of the segmental TD values are an indication of this (3). The 
commercial available Automated Function Imaging and auto LV quantification methods for 
2D and 3D speckle tracking strain have a user-friendly interface, but they are still very user 
dependent and require experienced critical judgement of the tracking of each segment. The 
2D strain speckle tracking method has a high degree of spatial smoothing by polynomial or 
spline fitting along the regions of interest. This software, like other commercially available 
speckle tracking tools, has limited opportunities to change preferences, and the technology 
behind the analyses is hidden for the user. The speckle tracking methods are regularly 
improved by the manufacturers, and during the work of this thesis, we have recognized 
improvements in the software. However, the tested 3D speckle tracing strain method suffered 
from low temporal and spatial resolution in 3D acquisitions and was very sensitive to acoustic 
artefacts.  
6.4 MRI acquisition and analysis 
LE-MRI is established as the reference standard for the quantification of myocardial scars 
(60, 63). We used the usual cut-off of 2 SD above the mean pixel intensity for identification 
of infarcted myocardium by LE-MRI. However this cut-off is not thoroughly validated and 
may result in overestimation of the true infarct size (137).  
6 Limitations 
7.1 General limitations  
All four studies were single centre studies, and the number of participants was low, 
particularly in study one. Thus, the studies have limited power to detect small differences 
 84 
between methods. Those differences however, can be assumed to be of less clinical 
importance. In study two, three, and four all echocardiographic analyses were done by one 
single operator, but care was taken to achieve blinded measurements for all methods, with 
different id-numbers for the echocardiographic and LE-MRI analyses. In addition, a subset of 
the recordings was reanalysed by one of the co-authors in order to calculate inter-analyser 
reproducibility. The greatest current limitation of echocardiography is subjectivity. 
Echocardiographic acquisition and analyses are operator dependent, and in particular 
deformation imaging require experienced critical judgement. Use of customized software 
makes it difficult for other centra to use the same methods in studies with similar study 
design. However, the customized software was the only available software with full 
information about segmental borders and wide opportunities to change preferences, and the 
process used to calculate myocardial deformation was not hidden for the user. 
Parameters of twist and torsion and 2D circumferential and radial strain were not 
analysed in any of the studies. Longitudinal strain tracks motion parallel to the ultrasound 
beam, where resolution is optimal in contrast to 2D circumferential and radial strain where 
motion is tracked in all directions. In addition, circumferential and radial strain is calculated 
from short-axis images, where image planes are not well standardized, and there is 
considerable through plane motion, especially in the basal parts of the heart. Thus, these 
methods might be less accurate due to methodological reasons as indicated by several studies 
(90, 91, 138), although one recent study has indicated added diagnostic value of 2D 
circumferential strain in patients with acute coronary syndromes (139).  
A subset of the recordings of all four studies had below average image quality. In 
clinical practice, echocardiographers might have considered use of contrast to achieve better 
image quality in these patients. Use of contrast was not allowed by the study protocol as one 
of the primary aims of the thesis was to evaluate the diagnostic accuracy of quantitative 
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deformation imaging, and the use of contrast precludes TD based quantitative measurements 
(140), as well as speckle tracking. On the other hand, particularly the accuracy of WMS, 
which was one of the best methods even without contrast, might have been expected to 
increase with the use of contrast. However, with contrast one evaluates endocardial motion 
more than wall thickening, which might mask tethering. Direct wall motion scoring by colour 
strain rate was not studied here, but has been shown to be reasonably similar in accuracy to B-
mode wall motion (19, 20).   
7.2 Specific limitations  
We sought to minimize biological variation by repeating the study over a short time frame, so 
that the main source of variation was related to imaging per se. However, biological variation 
over time is also clinically relevant, and performing repeated analyses with the same 
participants some weeks later would also have been valuable.  
 In study two, no patients with cardiac disease was included, and it remains to be tested 
whether our results could be extrapolated to a more general population of patients with heart 
disease, but we believe that the deliberate careful selection of a homogenous population of 
young and healthy students was favourable and may have contributed to clear and robust 
differences between the methods. On the other hand detection of inotropic alterations in 
healthy subjects is not the same as detection of cardiac dysfunction. Dobutamine and 
metoprolol were given to similar but not identical populations. However, the aim of the study 
was not to compare the effect of dobutamine against the effect of metoprolol as the effects of 
these drugs have been extensively studied previously. We gave dobutamine before metoprolol 
in seven subjects, and waited approximately 10 half lives before the subjects entered the 
metoprolol study, which should be enough to avoid residual effects among healthy subjects. 
However, there was a trend towards a smaller decrease in heart rate after injection of 
metoprolol among the 7 subjects who received dobutamine before metoprolol, but the 
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analyses of the echocardiographic indices did not indicate that these subjects responded 
significantly. No invasive reference method was used in study two and the subjects were not 
examined during changes in loading conditions (141). Furthermore, fully blinded analysis was 
not realistic in study two as the analyser easily could recognize if the myocardium was 
influenced by dobutamine.   
 In study three and four the healthy controls were not examined by LE-MRI. Therefore, 
the LE-MRI analyses were, in contrast to the echocardiographic analyses, performed without 
mixing healthy controls and MI patients. This might increase the prevalence of positive 
findings, as the MRI analyser had a priori knowledge that the patients actually had coronary 
artery disease. In study three and four, Anders Thorstensen examined the MI patients and 
Håvard Dalen examined the healthy controls. This might cause a systematic bias between the 
recordings of the MI patients and the healthy controls, but the extensive validation of the 
reproducibility between these echocardiographers showed excellent reproducibility for global 
indices and fair reproducibility for segmental indices. Although no patients were excluded due 
to poor image quality, there was probably a selection of patients with little co-morbidity 
mainly because of careful evaluation of the renal function prior to inclusion. In addition, prior 
MI and age >75 years were exclusion criteria. The 3D recordings were acquired with a 3V 
transducer. Later hardware versions have improved both volume rate and resolution, and this 
might have improved the 3D strain results.  
8 Conclusions 
Most traditional and newer echocardiographic indices of global LV function obtained with 
modern equipment allow reproducible measurements with moderate or strong correlations 
with LE-MRI in patients with recent MIs. Repeated analyses of the same recordings 
underestimate the clinically more relevant inter-observer reproducibility obtained by separate 
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examinations by approximately 40% for most measurements of LV function. Systolic annular 
excursion by M-mode and global average of segmental strain values showed the best inter-
observer reproducibility. Annular tissue Doppler measurements should be averaged from four 
sites instead of two, in order to optimize reproducibility. A major limitation of segmental 
measurements is high test-retest variability. 
Peak systolic velocity indices and end-systolic indices responded markedly different to 
inotropic alterations. Peak systolic velocity indices were most sensitive in detecting 
contraction changes, which indicates that peak systolic velocity indices might give important 
supplementary information to end-systolic indices like LVEF and global strain.  
Echocardiography performed approximately one month after myocardial infarction did 
show ability to identify the patients with infarct size >12 %, while most patients with infarct 
size <6 % did not have echocardiographic indices of impaired LV function. TD based colour 
coded strain rate added incremental diagnostic value to wall motion analysis in B-mode, and 
underscore the advantage of performing an integrated judgment, using more than one 
echocardiographic method. Dynamic multi-slice short-axis obtained from only one 3D 
recording gives a quick and reliable view of the LV regional function. As 3D WMS was one 
of the best methods and direct echocardiographic quantification of infarct size, showed the 
highest diagnostic accuracy in patients with MI, an overall conclusion is that 
echocardiography in three dimensions increases diagnostic accuracy.   
9 Future studies 
Reproducibility studies are clinically very relevant and also very instructive for the 
echocardiographic centres participating. Performing a larger test retest reproducibility study 
including 3D echocardiography of patients with various cardiac diseases would be interesting. 
Infarct size by LE-MRI yields prognostic information beyond LVEF (79). Hopefully, the 
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method of direct echocardiographic quantification of infarct size can be commercialized with 
a more user-friendly interface, and evaluating the prognostic value of this method in a 
prospective study would be attractive. Use of contrast, particularly for the 3D wall motion 
analyses, would probably be included if we perform a new study of patients with MI. There 
are plans for a 3D stress echocardiography study of patients with suspected coronary artery 
disease. However, as the relative frame rate decreases during peak stress, improvement in 
software and hardware would probably be necessary to achieve reliable 3D strain results in 
stress echocardiography. 
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